naltrexone has been researched along with nalmefene in 346 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 47 (13.58) | 18.7374 |
| 1990's | 77 (22.25) | 18.2507 |
| 2000's | 57 (16.47) | 29.6817 |
| 2010's | 133 (38.44) | 24.3611 |
| 2020's | 32 (9.25) | 2.80 |
| Authors | Studies |
|---|---|
| Cantrell, BE; Johnson, BG; Leander, JD; Mendelsohn, LG; Mitch, CH; Reel, JK; Shaw, WN; Snoddy, JD; Takemori, AE; Wong, DT | 1 |
| Adapa, ID; Auh, JS; Berzetei-Gurske, IP; Brandt, SR; Craymer, K; Farrington, L; Haggart, D; Kennedy, JM; O'Brien, A; Polgar, WE; Rodriguez, L; Schwartz, RW; Toll, L; White, A | 1 |
| Strassburg, CP; Tukey, RH | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Azar, MR; Berzetei-Gurske, I; Cashman, JR; Ghirmai, S; Polgar, WE | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bidlack, JM; Bu, Y; Cohen, DJ; Lou, R; Lu, Q; VanAlstine, MA; Wentland, MP | 1 |
| Azar, MR; Cashman, JR; Ghirmai, S | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Benzel, EC; Fowler, MR; Khare, V | 1 |
| Giles, A; Landymore, KM; Wilkinson, M | 1 |
| Bergasa, NV; Jones, EA | 1 |
| Han, J; Wang, T; Xu, T | 1 |
| de Zwaan, M; Mitchell, JE | 1 |
| Heisler, LE; Reid, RL; Van Vugt, DA | 1 |
| Millard, WJ; Simpkins, JW; Swager, D | 1 |
| Agresta, CA; Barone, CA; Freeman, GM; Puniak, MA; Salzman, SK; Van Newkirk, L | 1 |
| Wright, P; Yeomans, MR | 1 |
| Lopez, J; Naujokat, P; Toledo-Pereyra, LH; Walters, W; Xavier, R | 2 |
| Allen, JT; Brostrom, PA; DeHaven-Hudkins, DL; Ferkany, JW; Kaplita, PV; Lesko, LJ; Mavunkel, BJ; Rzeszotarski, WJ; Steranka, LR | 1 |
| Bakshi, R; Faden, AI; Newman, AH | 1 |
| Fudala, PJ; Heishman, SJ; Henningfield, JE; Johnson, RE | 1 |
| Billington, CJ; Morley, JE; Shafer, RB | 1 |
| Faden, AI; Yum, SW | 1 |
| Harrison, PV | 1 |
| Faden, AI; McIntosh, TK; Rhomhanyi, R; Vink, R | 1 |
| Chang, LH; Faden, AI; James, TL; Lemke, M; Shirane, R; Weinstein, PR | 1 |
| Caldwell, RW; Chryssanthis, A; Nagarajan, R; Tuttle, RR | 1 |
| Critchley, JA; Macleod, HA; Wright, P; Yeomans, MR | 1 |
| Reid, RL; Vanvugt, DA; Webb, MY | 2 |
| France, CP; Morse, WH | 1 |
| Cone, EJ; Fudala, PJ; Heishman, SJ; Henningfield, JE; Johnson, RE | 1 |
| Barsan, WG; Bartlett, R; Bryan, C; Buncher, R; Danzl, DF; Ling, LJ; Seger, D | 1 |
| Bardin, CW; Belhadj, H; de Besi, L; Thau, RB | 1 |
| Dixon, R; Hsiao, J; Hsu, HB; Morton, J; Pramanik, B; Smulkowski, M | 1 |
| Monroe, EW | 1 |
| Gentle, MJ; Savory, CJ; Yeomans, MR | 1 |
| Flood, JF; Morley, JE | 1 |
| Jacobson, AE | 1 |
| Bardin, CW; Boitani, C; Chen, CL; Gerendai, I; Margioris, AN; Morris, PL | 1 |
| Baile, CA; Gingerich, RL; McLaughlin, CL; Michel, ME | 1 |
| Bolger, G; Michel, ME; Weissman, BA | 1 |
| Imai, N; Kawashima, S; Liang, CS; Stone, CK; Tuttle, RR; Woolf, PD | 1 |
| Allen, JI; DeMaster, EG; Go, VL; Ho, SB; Levine, AS; Morley, JE; Shafer, RB | 1 |
| Burch, JR; Harrison, PV | 1 |
| Altman, DG; Barrowcliffe, MP; Jones, JG; Jordan, C; Konieczko, KM | 1 |
| Losowsky, MS; Thornton, JR | 1 |
| Court, MH; Dixon, R; Dodman, NH; Parker, D; Shuster, L; White, SD | 1 |
| Christopher, MA; Harman, E; Hendeles, L; Wyzan, D | 1 |
| Dixon, R; Simpkins, JW; Smulkowski, M; Tuttle, R | 1 |
| Fishman, J; Lustig, RH; Pfaff, DW | 2 |
| Billington, CJ; Brown, DM; Gosnell, BA; Grace, M; Krahn, DD; Levine, AS; Morley, JE | 1 |
| Faden, AI; Noble, LJ; Sacksen, I | 1 |
| Garris, DR; Michel, ME | 1 |
| Court, MH; Dodman, NH; Patel, J; Shuster, L | 1 |
| DiFazio, CA; Dixon, R; Gal, TJ | 1 |
| Bittle, JB; Givens, JR; Howes, JF; Karas, JG; Kitabchi, AE; Kurtz, BR; Mitchell, JA | 1 |
| Weiss, BL | 1 |
| Arteau, C; Fujimoto, JM; Roerig, SC | 1 |
| Cherkin, A; Flood, JF; Morley, JE | 1 |
| Dixon, R; Garg, D; Gentile, J; Howes, J; Hsiao, J; Hsu, HB; Weidler, D | 1 |
| Luby, ED; Marrazzi, MA | 1 |
| Kreeger, TJ; Plotka, ED; Seal, US | 1 |
| Bardin, CW; Gerendai, I; Gunsalus, GL; Shaha, C | 1 |
| Court, MH; Dixon, R; Dodman, NH; Shuster, L | 1 |
| Bardin, CW; Hahn, EF; Limonta, P; Thau, RB | 1 |
| Dixon, R; Garg, D; Gentile, J; Howes, J; Hsiao, J; Hsu, HB; Meyer, M; Tuttle, R; Weidler, D | 1 |
| DiFazio, CA; Gal, TJ | 1 |
| Feldman, M; Moore, L; Walsh, JH | 1 |
| Dixon, R; Hahn, E; Hsiao, J; Taaffe, W; Tuttle, R | 1 |
| Bodor, N; Katovich, MJ; Simpkins, JW; Song, IC; Tuttle, R | 1 |
| Bardin, CW; Gerendai, I; Shaha, C; Thau, R | 1 |
| Baile, CA; McLaughlin, CL | 1 |
| Dixon, R; Hsiao, J | 1 |
| Culpepper-Morgan, JA; Holt, PR; Kreek, MJ; LaRoche, D | 1 |
| Rault, B; Saiag, B; Shacoori, V | 1 |
| Goldberg, G; Mantero-Atienza, E; Mason, BJ; Morgan, RO; Ritvo, EC; Salvato, FR; Welch, B | 1 |
| Mason, BJ; Salvato, FR | 1 |
| Fujimoto, JM; Holmes, BB | 1 |
| Faden, AI; Graham, SH; Newman, A; Shimizu, H; Weinstein, P | 1 |
| France, CP; Gerak, LR | 1 |
| Kelsoe, JR; Konicki, PE; Pato, C; Pickar, D; Rapaport, MH; Wolkowitz, O | 1 |
| Glass, PS; Jhaveri, RM; Smith, LR | 1 |
| Glover, H | 1 |
| Stone, NN | 1 |
| Casper, RF; Graves, GR; Kennedy, TG; Weick, RF | 1 |
| Faden, AI | 1 |
| Kaplan, JL; Marx, JA | 1 |
| Beattie, MS; Behrmann, DL; Bresnahan, JC | 1 |
| Rust, M | 1 |
| Cobbe, SM; Hicks, MN; Oldroyd, KG | 1 |
| Albeck, H; Chou, JZ; Kreek, MJ | 1 |
| Bauman, M; Bullen, BA; Evans, WJ; Henley, K; McArthur, JW; Pehrson, J; Skrinar, GS; Turnbull, BA; Turner, A | 1 |
| Chami, TN; Cheskin, LJ; Jaffe, JH; Johnson, RE | 1 |
| Osifchin, E; Veng-Pedersen, P; Waters, SJ; Wilhelm, JA; Zakszewski, TB | 2 |
| O'Malley, SS | 1 |
| Girre, A; Lemay, V; Rault, B; Saïag, B; Shacoori, V | 1 |
| Kvalo, LT; Lessor, RA; Mathur, C; Murthy, SS; Wilhelm, JA | 1 |
| Alexander, AC; Dixon, R; Frye, RF; Johnston, J; Matzke, GR; Rault, RM; Reynolds, R | 1 |
| Bikhazi, GB; Frye, RF; Jallad, NS; Matzke, GR; Wilhelm, JA | 1 |
| Mason, BJ | 1 |
| Brittain, HG; Murthy, SS | 1 |
| Litten, RZ | 1 |
| Henderson, CA; Reynolds, JE | 1 |
| Capodano, RJ; Gaeta, TJ; Spevack, TA | 1 |
| Dixon, R; Frye, RF; Matzke, GR; Rabinovitz, M; Schade, R | 1 |
| Civelek, AC; Dannals, RF; Dixon, RB; Joh, T; Kao, PF; Kim, S; Ravert, HT; Villemagne, VL; Wagner, HN | 1 |
| Kakiuchi, T; Kosugi, T; Kreek, MJ; Nishiyama, S; Tsukada, H; Unterwald, EM | 1 |
| Hernandez, AV; Norton, JA; Storrow, AB | 1 |
| Deal, DD; Dewitt, DS; Prough, DS; Uchida, T; Vines, SM | 1 |
| Alling, DW; Bergasa, NV; Jenkins, JB; Jones, EA; Schmitt, JM; Swain, MG; Talbot, TL; Turner, ML | 1 |
| Kim, SW | 1 |
| Sinclair, JD | 1 |
| Manara, AR; Merriman, RJ; Mills, IH; Park, GR | 1 |
| Borg, L; Gunduz, M; Ho, A; King, A; Kreek, MJ; Maniar, S; Perret, G; Porter, M; Schluger, JH | 1 |
| Chow, BL; Sellers, EM; Tomkins, DM | 1 |
| Borg, L; Gunduz, M; Ho, A; Kreek, MJ; Schluger, J | 1 |
| Cummings, R; Durr, LF; Grey, C; Johnson, A; June, HL; Lawrence, A; Mason, D; McCane, S; Ricks-Cord, A; Warren-Reese, C; Williams, LS | 1 |
| Chehade, J; Duffy, L; Gajraj, N; Johnson, ER; Joshi, GP; Wesevich, J | 1 |
| Carey, TS; Crews, FT; Garbutt, JC; Lohr, KN; West, SL | 1 |
| Chumpa, A | 1 |
| Calabro, JJ; Gaddis, GM; Gin-Shaw, SL; Harchelroad, FP; Kaplan, JL; Marx, JA; Spiller, JD; Spivey, WL; Zhao, N | 1 |
| Cutler, RB; Mason, BJ; Ritvo, EC; Salvato, FR; Williams, LD | 1 |
| Alling, DW; Bergasa, NV; Jones, EA; Talbot, TL; Wells, MC | 1 |
| Cullen, DJ; Dwyer, MJ; Gold, CG; Gonzales, S; Houtmeyers, D | 1 |
| Ko, MC; Naughton, NN | 1 |
| Dougherty, TB; Porche, VH; Thall, PF | 1 |
| Anton, RF; Drobes, DJ | 1 |
| Fudala, PJ; Heishman, SJ; Henningfield, JE; Johnson, RE; Jones, HE | 1 |
| Clark, WM; Kelly, RE; Raps, EC; Tong, DC | 1 |
| Kelly, M; Mello, NK; Mendelson, JH | 1 |
| Chang, CT; Frye, RF; Gustafson, RA; Morris, JL; Nelson, ER; Rosen, DA; Rosen, KR; Steelman, RJ; Thackara, JW; Wilhelm, JA | 1 |
| Jarusuraisin, N; Srisurapanont, M | 2 |
| Inagaki, N; Kawasaki, H; Nagai, H; Nagao, M; Nakamura, N | 1 |
| Brady, KT; Malcolm, R; Myrick, H | 1 |
| Bilsky, EJ; Raehal, KM; Sadée, W; Wang, D | 1 |
| Anton, RF | 1 |
| Burns, MM; Chumpa, A; Kaplan, RL; Shannon, MW | 1 |
| Borrow, J; O'Leary, G; Weiss, RD | 1 |
| Bailey, SL; Faut-Callahan, M; Graves, J; Paice, JA; Pellegrini, JE; Shott, S | 1 |
| Biegner, AR; DiChiara, SE; Hawkins, RJ; Lawrence, RL; Vacchiano, CA; Ward, RC | 1 |
| Allen, D; Cooper, TB; Mason, BJ; Suckow, RF; Xie, S | 1 |
| Sareen, D | 1 |
| Commons, KG; Kow, LM; Ogawa, S; Pfaff, DW | 1 |
| Anton, RF; Drobes, DJ; Thomas, SE; Voronin, K | 2 |
| Ko, MC; Lee, H; Naughton, NN; Woods, JH | 1 |
| Cummings, R; Eiler, WJ; Foster, KL; Garcia, M; Grey, C; Hawkins, SE; June, HL; Mason, D; McCane, S; McKay, PF; Seyoum, R | 1 |
| Chen, RZ; Fong, TM; Huang, RR; MacNeil, DJ; Shen, CP | 2 |
| Salaspuro, M | 1 |
| Anthenelli, R; Anton, RF; Bohn, MJ; Galloway, G; Garbutt, J; Gastfriend, D; Johnson, B; Kallio, A; Karhuvaara, S; Kranzler, HR; McCaul, ME; Pettinati, H; Salloum, I; Swift, R; Zweben, A | 1 |
| Azar, MR; Costantini, LC; Kleppner, SR; McDonough, J; Patel, R | 1 |
| Andrenyak, DM; Fang, WB; Moody, DE; Nuwayser, ES | 1 |
| Aalto, S; Hagelberg, N; Hietala, J; Ingman, K; Juhakoski, A; Kallio, A; Karhuvaara, S; Någren, K; Oikonen, V; Scheinin, H | 1 |
| Bart, G; Bidlack, JM; Borg, L; Ho, A; Kreek, MJ; Schluger, JH | 1 |
| Koppeschaar, HP; Schagen Van Leeuwen, JH; Te Velde, ER; Van Ree, JM | 1 |
| Conwell, IM; Freda, PU; Geer, EB; Landman, RE; Wardlaw, SL | 1 |
| Adaikan, G; Becher, E; Brock, G; Carrier, S; Carson, C; Christ, G; Corbin, J; DeBusk, R; Eardley, I; Francis, S; Hedlund, H; Hutter, A; Jackson, G; Kloner, R; Lin, CS; Lin, S; McCullough, A; McVary, K; Nehra, A; Padma-Nathan, H; Porst, H; Schulman, C; Seftel, A; Sharlip, I; Stief, C; Teloken, C | 1 |
| Nestler, EJ; Tamminga, CA | 1 |
| Cunningham-Williams, R; Grant, JE; Hollander, E; Kallio, A; Nurminen, T; Potenza, MN; Smits, G | 1 |
| Gao, YL; Li, G; Wu, XG | 1 |
| Butelman, ER; Kreek, MJ; Mandau, M; Prisinzano, TE; Tidgewell, K; Yuferov, V | 1 |
| Du, G; Gao, Y; Nie, S; Pan, W | 1 |
| Chen, X; Dai, X; Li, P; Wen, A; Zhang, Y; Zhong, D | 1 |
| Cottone, P; Sabino, V; Steardo, L; Zorrilla, EP | 1 |
| Kallio, A; Karhuvaara, S; Löyttyniemi, E; Mäkelä, R; Nurminen, T; Rosberg, M; Simojoki, K; Virta, A | 1 |
| Koob, GF; Walker, BM | 1 |
| June, HL | 1 |
| Arias, AJ; Armeli, S; Covault, J; Gelernter, J; Kallio, A; Karhuvaara, S; Koivisto, T; Kranzler, HR; Mäkelä, R | 1 |
| Grant, JE; Hollander, E; Kim, SW; Potenza, MN | 1 |
| Liao, RF; Wen, YG; Zeng, ZP | 1 |
| Blanco, C; Grant, JE; Hollander, E; Kim, SW; Potenza, MN | 1 |
| Rösner, S; Soyka, M | 2 |
| Ali, R; Gowing, L; White, JM | 1 |
| Bilsky, EJ; Giuvelis, D; Lowery, JJ; Osborn, MD; Skorput, AG | 1 |
| Bernhard, JD; Luger, TA; Phan, NQ; Ständer, S | 1 |
| Liu, HT; Wang, HL; Yu, KJ | 1 |
| Grant, JE; Hollander, E; Kim, SW; Odlaug, BL; Potenza, MN | 1 |
| Cheng, XR; Sheng, GY; Zhang, Q | 1 |
| Hackl-Herrwerth, A; Leucht, S; Rösner, S; Soyka, M; Srisurapanont, M; Vecchi, S | 1 |
| Clemens, MG; Day, SA; Lakner, AM; Moore, CC; Schrum, LW; Wu, ES; Yen, MH | 1 |
| Rezazadeh, M; Seidi, S; Yamini, Y | 1 |
| Abramovits, W; Draelos, Z; Duffy, M; Fleischer, A; Green, E; Herzog, JL; Rothaul, A; Solomon, JA; Stough, D; Tansley, R; Werschler, W; Wolf, DI | 1 |
| Andersen, MP; Graff, C; Højer, AM; Kallio, A; Kanters, JK; Matz, J; Struijk, JJ; Toft, E; Vainio, PJ | 1 |
| Lumbad, J; Yancey, JR | 1 |
| Diatchenko, L; Ding, F; Dokholyan, NV; Gauthier, J; Gibson, DG; Maixner, W; Serohijos, AW; Yin, S | 1 |
| Spanagel, R; Vengeliene, V | 1 |
| Esrafili, A; Rezazadeh, M; Seidi, S; Yamini, Y | 2 |
| Bont, L; Coenjaerts, FE; Hennus, MP; Hodemaekers, HM; Janssen, R; Meyaard, L; Mokhtari-Azad, T; Rygiel, TP; Salimi, V; Shokri, F | 1 |
| Bladström, A; Gual, A; Mann, K; Torup, L; van den Brink, W | 1 |
| Swift, RM | 1 |
| Gual, A; He, Y; Mann, K; Torup, L; van den Brink, W | 1 |
| Aubin, HJ; Daeppen, JB | 1 |
| Franck, J; Jayaram-Lindström, N | 1 |
| Arias, AJ; Niciu, MJ | 1 |
| Keating, GM | 1 |
| Soyka, M | 3 |
| Heinz, A; Müller, CA | 1 |
| Spence, D | 1 |
| Batel, P; Chick, J; Gual, A; Kiefer, F; Sinclair, J; Sørensen, P | 1 |
| Braillon, A | 2 |
| McNulty, SJ; Williams, P | 1 |
| Gual, A; Mann, K; Sørensen, P; Torup, L; van den Brink, W | 1 |
| Amick, HR; Bobashev, G; Feltner, C; Garbutt, JC; Gass, CE; Jonas, DE; Kim, MM; Rowe, CJ; Shanahan, E; Thomas, K; Wines, R | 1 |
| Dong, H; Gao, X; Gong, Z; Ma, W; Su, R; Yong, Z | 1 |
| Bruguera, P; Gual, A; López-Pelayo, H | 1 |
| Bullmore, ET; Felici, A; Henderson, G; Kelly, E; Maltby, K; Mundell, SJ; Nathan, PJ; Roth, AL; Sava, A | 1 |
| Barbosa, C; Brodtkorb, TH; Daeppen, JB; François, C; Knight, C; Laramée, P; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Aballéa, S; Bineau, S; Chalem, Y; François, C; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Wise, J | 1 |
| Chen, R; Guo, R; Li, H; Lin, S; Liu, M; You, C; Zheng, J | 1 |
| Borro, P; Leone, S; Testino, G | 1 |
| Bilbao, A; Heilig, M; Malanga, CJ; Robinson, JE; Sommer, WH; Spanagel, R; Thorsell, A | 1 |
| Nubukpo, P | 1 |
| Bendimerad, P; Blecha, L | 1 |
| Stafford, N | 1 |
| Grosshans, M; Kiefer, F; Mutschler, J | 1 |
| Gual, A; Jensen, TJ; Mann, K; Strang, J; Sørensen, P; van den Brink, W | 1 |
| Lieb, M; Soyka, M | 1 |
| Aubin, HJ; Bladström, A; Chick, J; François, C; Nutt, DJ; Reimer, J; Torup, L | 1 |
| Morgan, MY; Pandor, A; Rawdin, A; Rice, P; Stevens, JW; Stevenson, M; Thompson, J | 1 |
| Chi, Q; Li, M; Li, Y; Li, Z; Lin, W; Xie, X; Xing, C; Yang, Y; Yang, Z; Zhang, H | 1 |
| Favrod-Coune, T | 1 |
| Donnerstag, N; Lüthi, A; Mehlig, A; Raetz Bravo, A; Schneider, T; Taegtmeyer, A | 1 |
| Aubin, HJ; Chalem, Y; François, C; Luquiens, A; Rahhali, N; Sørensen, P | 1 |
| Baroni, S; Dell'Osso, L; Marazziti, D; Mucci, F; Mungai, F; Piccinni, A; Presta, S | 1 |
| Agabio, R; Franconi, F; Gessa, GL; Pani, PP; Preti, A | 1 |
| Laramée, P; Rahhali, N; Rehm, J; Roerecke, M; Sørensen, P | 1 |
| Bruhn, C | 1 |
| Higuchi, S; Yumoto, Y | 1 |
| Bhuiyan, TA; Graff, C; Kanters, JK; Matz, J; Melgaard, J; Nielsen, J; Struijk, JJ; Toft, E | 1 |
| Serecigni, JG | 1 |
| Dahmke, H; Kullak-Ublick, GA; Kupferschmidt, H; Weiler, S | 1 |
| Areberg, J; Faerch, KU; Kyhl, LE; Larsen, F; Li, S; Soegaard, B | 1 |
| Sivolap, YP | 1 |
| Baroni, S; DellʼOsso, L; Marazziti, D; Piccinni, A | 1 |
| Hackett, D; Heal, DJ; Hutson, PH; Murray, F; Vickers, SP | 1 |
| Franchitto, N; Nubukpo, P; Pélissier, F; Rougé Bugat, ME | 1 |
| Bellissant, E; Boussageon, R; Laviolle, B; Naudet, F; Palpacuer, C; Reymann, JM | 1 |
| Martelli, A; Mattioli, F; Milano, G; Natta, WM; Zavan, V | 1 |
| Fontenelle, LF; Piquet-Pessôa, M | 1 |
| Bell, M; Brodtkorb, TH; Irving, A; Laramée, P | 1 |
| Friede, M; Schnitker, J; Soyka, M | 2 |
| Addolorato, G; Bernardi, M; Caputo, F; D'Amore, A; Domenicali, M; Maremmani, AG; Maremmani, I; Zoli, G | 1 |
| Bell, M; Brodtkorb, TH; Irving, AH; Laramée, P | 1 |
| Dudek, M; Herr, DR; Hytönen, HR; Hyytiä, P; Korpi, ER; Linden, AM; Paasikoski, N; Vashchinkina, E | 1 |
| Annaert, PP; Atack, JR; Borghys, H; de Vries, R; De Zwart, LL; Embrechts, RC; Gaekens, T; Guillaume, M; Herdewijn, P; Leysen, JE; Megens, AA; Vermeulen, A | 1 |
| Bühler, KM; Calleja-Conde, J; Echeverry-Alzate, V; Giné, E; Gual, A; López-Moreno, JA; Maldonado, R; Nadal, R; Rodríguez de Fonseca, F | 1 |
| Braillon, A; Granger, B; Naudet, F | 1 |
| Angus, K; de Andrade, M; Elders, A; Fitzgerald, N; Heather, N; McCambridge, J; Raistrick, D | 1 |
| Aballéa, S; Chalem, Y; Cristeau, O; François, C; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Naudet, F | 1 |
| Bramness, JG; Mann, K; Wurst, FM | 1 |
| Aballéa, S; Brodtkorb, TH; Cristeau, O; Laramée, P; Millier, A; Montgomery, S; Rahhali, N; Rehm, J; Steeves, S; Toumi, M | 1 |
| Jones, SR; Karkhanis, AN; Rose, JH; Steiniger-Brach, B | 1 |
| Boussageon, R; Laviolle, B; Naudet, F; Palpacuer, C | 1 |
| Gual, A; Mann, K; Swift, R; Sørensen, P; Torup, L; van den Brink, W; Walker, B | 1 |
| Braillon, A; Fitzgerald, N; Naudet, F | 1 |
| Carmona, C; Elices, M; Gasol, M; Gasol, X; Martín-Blanco, A; Pascual, JC; Patrizi, B; Soler, J | 1 |
| Bolstridge, M; Boyce, M; Breuning Sluth, L; Flechais, RSA; Lingford-Hughes, A; McGonigle, J; Meulien, D; Mick, I; Newbould, RD; Nutt, D; Quelch, DR; Rabiner, E; Ramos, AC; Steiniger-Brach, B; van den Berg, F; von der Goltz, C; Wall, MB; Østergaard Nilausen, D | 1 |
| Allen, AR; Balleine, B; Carter, A; Clark, L; Dowling, NA; Gainsbury, SM; Goudriaan, AE; Grant, J; Hall, W; Hayes, A; Hodgins, D; Lattimore, R; Livingstone, C; Lorenzetti, V; Lubman, D; Murawski, C; Parkes, L; Petry, N; Room, R; Singh, B; Thomas, A; Townshend, P; van Holst, R; Youssef, G; Yücel, M | 1 |
| Goh, ET; Morgan, MY | 1 |
| Gibaja, V; Gillet, P; Labroca, P; Lemarié, J; Martini, H; Paille, F; Petitpain, N; Yéléhé-Okouma, M | 1 |
| Franchitto, N; Jullian, B; Pelissier, F; Rolland, B; Salles, J | 1 |
| Gil, A; Guerri, C; Montesinos, J | 1 |
| Lyon, J | 1 |
| De Filippis, S; De Persis, S; De Risio, L; di Giannantonio, M; Di Nicola, M; Janiri, L; Maremmani, AGI; Maremmani, I; Martinotti, G; Pettorruso, M | 1 |
| Carton, L; Gaboriau, L; Lescut, C; Rolland, B | 1 |
| Bidlack, JM; Callaghan, CK; Dean, RL; Deaver, DR; Knapp, BI; O'Mara, SM; Rouine, J | 1 |
| Astrup, A; Christensen, R; Johansen, KGV; Lund, H; Pagsberg, AK; Tarp, S | 1 |
| Boussageon, R; Duprez, R; Huneau, A; Laviolle, B; Locher, C; Naudet, F; Palpacuer, C | 1 |
| Barrio, P; Gual, A; Guardia, J; Ortega, L; Roncero, C; Yuguero, L | 2 |
| Aballéa, S; Daeppen, JB; Laramée, P; Millier, A; Rahhali, N; Rehm, J; Toumi, M | 1 |
| Bont, L; Gharagozlou, MJ; Golara, M; Jamali, A; Mahmoodi, M; Minaei, B; Mirzaei, H; Mokhtari-Azad, T; Ramezani, A; Salimi, V; Shahabi, S; Shokri, F; Tahamtan, A | 1 |
| Chen, W; Chen, X; Miao, C; Sun, P; Sun, Z; Wang, J; Weng, M; Wu, Q; Zhu, M | 1 |
| Donoghue, K | 1 |
| Bernoussi, A; Braillon, A; Taiebi, F | 1 |
| Arbib, F; Khouri, C; Pepin, JL; Revol, B; Tamisier, R | 1 |
| Ahmad, SU; Kumar, J; Mohamed, IN; Pakri Mohamed, RM | 1 |
| Diouf, M; González-Marín, MC; Jeanblanc, J; Lebourgeois, S; Naassila, M | 1 |
| Kreek, MJ; Reed, B; Windisch, KA | 1 |
| Barrio Giménez, P; Gual, A; Guardia, J; Ortega, L; Roncero, C; Yuguero, L | 1 |
| Fauconneau, B; Favrelière, S; Lafay-Chebassier, C; Montastruc, F; Pérault-Pochat, MC; Quillet, A; Yéléhé-Okouma, M | 1 |
| Chaignot, C; Coste, J; Dray-Spira, R; Rey, G; Weill, A; Zureik, M | 1 |
| An, J; Chen, C; Li, X; Lu, H; Tan, R; Wang, F; Wang, J; Wu, G; Zhao, X | 1 |
| Bramness, JG; Heldal, AT; Lobmaier, PPK; Skurtveit, S; Vederhus, JK | 1 |
| Brix Schou, M; Brotons, C; Castera, P; Großkopf, J; Meulien, D; Steiniger Brach, B; Stewart, E; Zhang, D | 1 |
| Baharfar, M; Faraji, M; Yamini, Y; Zarghampour, F | 1 |
| Crystal, R; Gyaw, S; Krieter, P; Skolnick, P | 1 |
| Alho, H; Castrén, S; Mäkelä, N | 1 |
| Hayashi, T; Higuchi, S; Meulien, D; Miyata, H; Murai, Y; Sørensen, P; Takahashi, M; Tsuneyoshi, K | 1 |
| Duprez, R; Hammas, K; Ioannidis, JPA; Laviolle, B; Naudet, F; Palpacuer, C | 1 |
| Braillon, A; Naudet, F; Palpacuer, C | 1 |
| Brach, BS; Luderer, M; Meulien, D; Mueller, S; Schou, MB; Zhang, D | 1 |
| Bumb, JM; Dinter, C; Hermann, D; Karl, D; Kiefer, F; Koopmann, A; Mann, K; Otto, A; Vollstädt-Klein, S | 1 |
| Caballeria, E; Gual, A; López-Pelayo, H; Mann, K; Van den Brink, W; Zuluaga, P | 1 |
| Hayashi, T; Higuchi, S; Miyata, H | 1 |
| Kang, P; Wang, HQ; Yang, J; Yang, P; Zhang, NL; Zhao, T | 1 |
| Browne, CA; Lucki, I; Smith, T | 1 |
| Kunzler, NM; Nelson, LS; Wightman, RS | 1 |
| Butelman, ER; Fry, RS; Kimani, R; Kreek, MJ; Reed, B | 1 |
| Tadori, Y | 1 |
| Mueller, S | 1 |
| Chen, Y; Fu, C; Hu, R; Huang, C; Jiang, H; Li, C; Sun, Y; Tang, D; Wang, H; Yan, J; Zhu, J | 1 |
| Higuchi, S; Meulien, D; Miyata, H; Murai, Y; Nakamura, I; Takahashi, M; Tsuneyoshi, K | 1 |
| Ohgi, Y | 1 |
| Tamaki, K | 1 |
| Corso, R; Ferguson, FJ; McFadden, JP; White, IR | 1 |
| Bach, P; Bumb, JM; Dinter, C; Hermann, D; Karl, D; Kiefer, F; Koopmann, A; Mann, K; Vollstädt-Klein, S | 1 |
| García, MC | 1 |
| Andersohn, F; Aubin, HJ; Blin, P; Dureau-Pournin, C; Falissard, B; Micon, S; Paille, F; Pénichon, M; Rigaud, A; Truchi, C | 1 |
| Kreek, MJ; Morochnik, M; Reed, B; Windisch, KA | 1 |
| Gao, J; Li, H; Wang, H; Wang, X; Wang, Y; Wu, S; Xie, J; Zhang, T; Zhang, X | 1 |
| Andersohn, F; Borchert, K; Braun, S; Chick, J; Guillo, S; Haas, JS; Kuppan, K; Lemming, OM; Reines, EH; Toussi, M; Tubach, F | 1 |
| Narayan, RJ; Papich, MG | 1 |
| Enning, F; Schmahl, C | 1 |
| Habu, H; Hashimoto, N; Kishi, Y; Matsuo, K; Okahisa, Y; Sakamoto, S; Takaki, M; Takao, S; Yamada, N | 1 |
| Gerhardt, S; Grundinger, N; Karl, D; Kiefer, F; Mann, K; Vollstädt-Klein, S | 1 |
| Han, X; Li, M; Nie, G; Zhang, T; Zheng, A | 1 |
| Wang, Z; Zhan, Y; Zhang, J; Zhao, Z | 1 |
| Harris, E | 1 |
| Nawata, Y; Nishioku, T; Ooishi, R; Yamaguchi, T | 1 |
62 review(s) available for naltrexone and nalmefene
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
Opiate antagonists and eating behavior in humans: a review.
Topics: Appetite Depressants; Dose-Response Relationship, Drug; Eating; Feeding and Eating Disorders; Feeding Behavior; Female; Humans; Male; Naloxone; Naltrexone; Narcotic Antagonists; Obesity | 1992 |
Biological evaluation of compounds for their physical dependence potential and abuse liability. X. Drug testing programs of the Committee on Problems of Drug Dependence, Inc. (1986).
Topics: 3,4-Methylenedioxyamphetamine; Animals; Appetite Depressants; Bridged-Ring Compounds; Chemical Phenomena; Chemistry; Meptazinol; N-Methyl-3,4-methylenedioxyamphetamine; Naltrexone; Narcotics; Substance-Related Disorders | 1987 |
[Prevention of undesirable effects during the use of opiate antagonists].
Topics: Humans; Naloxone; Naltrexone; Narcotic Antagonists | 1993 |
Dosing issues in the pharmacotherapy of alcoholism.
Topics: Administration, Oral; Adult; Alcoholism; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Imipramine; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 1996 |
Pharmacological treatment of alcohol dependence: a review of the evidence.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcoholism; Disulfiram; Humans; Lithium; Naltrexone; Narcotic Antagonists; Serotonin Agents; Taurine | 1999 |
Nalmefene hydrochloride.
Topics: Clinical Trials as Topic; Drug Overdose; Half-Life; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics | 1999 |
Opioid antagonists for alcohol dependence.
Topics: Alcoholism; Controlled Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2000 |
New developments in the pharmacotherapy of alcohol dependence.
Topics: Acamprosate; Adjuvants, Anesthesia; Alcohol Deterrents; Alcoholism; Anticonvulsants; Buspirone; Carbamazepine; Drug Therapy; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Ritanserin; Serotonin Agents; Sodium Oxybate; Substance Withdrawal Syndrome; Taurine; Valproic Acid; Vigabatrin | 2001 |
Pharmacologic approaches to the management of alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Behavior, Addictive; Clinical Trials as Topic; Disulfiram; Humans; Naltrexone; Narcotic Antagonists; Taurine; Treatment Outcome | 2001 |
Opioid antagonists in the treatment of alcohol dependence.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2001 |
Neuroprotective agents in acute ischemic stroke.
Topics: Acute Disease; Adult; Aged; Animals; Antioxidants; Calcium Channel Blockers; Chlormethiazole; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Excitatory Amino Acid Antagonists; Excitatory Amino Acids; Forecasting; GABA Modulators; Guanidines; Humans; Imidazoles; Middle Aged; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Pipecolic Acids; Piperidines; Quinoxalines; Rats; Receptors, N-Methyl-D-Aspartate; Reperfusion Injury; Stroke; Thiazoles | 2002 |
[Drug therapy of alcohol dependence--a critical review].
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Anticonvulsants; Fructose; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Taurine; Topiramate | 2003 |
Opioid antagonists for alcohol dependence.
Topics: Alcoholism; Controlled Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2005 |
Opioid antagonists for pharmacological treatment of alcohol dependence - a critical review.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Delayed-Action Preparations; Dopamine; Drug Therapy, Combination; Humans; Motivation; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Receptors, Opioid; Secondary Prevention; Taurine; Temperance; Ventral Tegmental Area | 2008 |
Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal.
Topics: Anesthetics; Humans; Hypnotics and Sedatives; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome | 2010 |
Antipruritic treatment with systemic μ-opioid receptor antagonists: a review.
Topics: Administration, Oral; Antipruritics; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Naloxone; Naltrexone; Pruritus; Randomized Controlled Trials as Topic; Receptors, Opioid, mu; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2010 |
Nalmefene for treatment of alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Animals; Clinical Trials as Topic; Humans; Naltrexone | 2010 |
Opioid antagonists for alcohol dependence.
Topics: Alcoholism; Controlled Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2010 |
Opioid antagonists for the treatment of alcohol dependence.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Motivation; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Secondary Prevention; Taurine; Treatment Outcome | 2011 |
New pharmacological treatment strategies for relapse prevention.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Animals; Disulfiram; Drugs, Investigational; History, 18th Century; History, 21st Century; Humans; Naltrexone; Receptors, N-Methyl-D-Aspartate; Secondary Prevention; Taurine | 2013 |
Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption.
Topics: Alcohol Abstinence; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Aripiprazole; Flupenthixol; Fluvoxamine; Fructose; Humans; Naltrexone; Piperazines; Psychotropic Drugs; Quinolones; Topiramate | 2013 |
Pharmacotherapy for alcohol dependence: status of current treatments.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Disulfiram; Humans; Multicenter Studies as Topic; Naltrexone; Narcotic Antagonists; Taurine | 2013 |
Targeted opioid receptor antagonists in the treatment of alcohol use disorders.
Topics: Alcohol-Related Disorders; Clinical Trials as Topic; Humans; Molecular Targeted Therapy; Naltrexone; Narcotic Antagonists; Receptors, Opioid; Treatment Outcome | 2013 |
Nalmefene: a review of its use in the treatment of alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Double-Blind Method; Humans; Internationality; Naltrexone; Randomized Controlled Trials as Topic | 2013 |
[Nalmefene: a novel pharmacotherapeutic option for alcoholism].
Topics: Alcoholism; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2014 |
Nalmefene for the treatment of alcohol dependence: a current update.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2014 |
[New treatment options for alcohol dependence].
Topics: Acamprosate; Alcoholism; Baclofen; Combined Modality Therapy; Ethanol; Fructose; Humans; Naltrexone; Psychotherapy; Secondary Prevention; Socioenvironmental Therapy; Substance Withdrawal Syndrome; Taurine; Topiramate | 2013 |
Bad medicine: nalmefene in alcohol misuse.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Neuroprotective Agents | 2014 |
Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
Topics: Acamprosate; Alcohol-Related Disorders; Fructose; Harm Reduction; Humans; Naltrexone; Outpatients; Randomized Controlled Trials as Topic; Taurine; Topiramate | 2014 |
Nalmefene and its use in alcohol dependence.
Topics: Alcoholism; Drug Interactions; Humans; Naltrexone | 2014 |
Treatment of alcohol dependence: recent progress and reduction of consumption.
Topics: Acamprosate; Age of Onset; Alcohol Deterrents; Alcohol-Related Disorders; Alcoholism; Binge Drinking; Contraindications; Craving; Disulfiram; Drugs, Investigational; Europe; Humans; Meta-Analysis as Topic; Multicenter Studies as Topic; Naltrexone; Neurotransmitter Agents; Randomized Controlled Trials as Topic; Sodium Oxybate; Taurine | 2014 |
[Place of the opioid system in biology and treatment of Alcohol Use Disorder].
Topics: Alcoholism; Brain; Craving; Diagnostic and Statistical Manual of Mental Disorders; Dynorphins; Endorphins; Humans; International Classification of Diseases; Naltrexone; Neurotransmitter Agents; Receptors, Opioid | 2014 |
[Benefits in reducing alcohol consumption: how nalmefene can help].
Topics: Adolescent; Adult; Alcohol Drinking; Alcoholism; Behavior Therapy; Cause of Death; Europe; Female; Humans; Male; Middle Aged; Naltrexone; Risk Factors; Treatment Outcome; Young Adult | 2014 |
[Nalmefene (Selincro) orally].
Topics: Administration, Oral; Alcohol Deterrents; Alcoholism; Humans; Naltrexone | 2014 |
Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
Topics: Adult; Alcohol Drinking; Alcoholism; Clinical Trials, Phase III as Topic; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Recent Developments in Pharmacotherapy of Alcoholism.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Anticonvulsants; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Pharmacogenetics; Randomized Controlled Trials as Topic; Taurine; Varenicline | 2015 |
Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adult; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost-Benefit Analysis; Humans; Naltrexone; Narcotic Antagonists; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Social Support | 2015 |
Nalmefene: A Novel Drug for an Old Disorder.
Topics: Alcohol Drinking; Alcoholism; Animals; Humans; Naltrexone | 2015 |
Efficacy of Medications Approved for the Treatment of Alcohol Dependence and Alcohol Withdrawal Syndrome in Female Patients: A Descriptive Review.
Topics: Acamprosate; Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcoholism; Anticonvulsants; Benzodiazepines; Disulfiram; Female; Humans; Male; Naltrexone; Sex Factors; Taurine; Treatment Outcome | 2016 |
Clinical relevance of nalmefene versus placebo in alcohol treatment: reduction in mortality risk.
Topics: Alcoholism; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Randomized Controlled Trials as Topic | 2015 |
[Pharmacological therapies for alcohol use disorder in Japan].
Topics: Acamprosate; Alcohol-Related Disorders; Alcohols; Humans; Japan; Naltrexone; Substance Withdrawal Syndrome; Taurine | 2015 |
Opioid Receptor Antagonists in the Treatment of Alcoholism.
Topics: Alcoholism; Animals; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists | 2015 |
Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2015 |
Opioid antagonists in broadly defined behavioral addictions: a narrative review.
Topics: Alcoholism; Bulimia; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Gambling; Humans; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Randomized Controlled Trials as Topic; Trichotillomania | 2016 |
Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential.
Topics: Alcoholism; Animals; Clinical Trials, Phase III as Topic; Harm Reduction; Hospitalization; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2016 |
The Cost-Effectiveness of the Integration of Nalmefene within the UK Healthcare System Treatment Pathway for Alcohol Dependence.
Topics: Alcoholism; Clinical Trials as Topic; Combined Modality Therapy; Cost-Benefit Analysis; Health Care Costs; Humans; Markov Chains; Models, Economic; Naltrexone; Psychotherapy; Quality-Adjusted Life Years; Treatment Outcome | 2016 |
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
Topics: Adult; Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers.
Topics: Alcoholism; Drug Approval; Europe; Evidence-Based Medicine; Humans; Naltrexone; Narcotic Antagonists; Practice Guidelines as Topic; United Kingdom | 2016 |
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-analysis - Comment to Naudet.
Topics: Alcoholism; Appetite Depressants; Humans; Naltrexone; Narcotic Antagonists | 2016 |
Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy.
Topics: Alcohol Deterrents; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu | 2016 |
Neuroscience in gambling policy and treatment: an interdisciplinary perspective.
Topics: Administrative Personnel; Appetite Depressants; Decision Making; Diagnostic and Statistical Manual of Mental Disorders; Disruptive, Impulse Control, and Conduct Disorders; Gambling; Harm Reduction; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Neurosciences; Public Health | 2017 |
Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Baclofen; Disulfiram; Drug Combinations; Fructose; Humans; Naltrexone; Polymorphism, Single Nucleotide; Pyridoxine; Pyrrolidonecarboxylic Acid; Taurine; Topiramate; Treatment Outcome | 2017 |
Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians.
Topics: Alcoholism; Analgesics, Opioid; Animals; Drug Interactions; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Risk Factors; Substance Withdrawal Syndrome | 2017 |
Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials.
Topics: Disruptive, Impulse Control, and Conduct Disorders; Humans; Naltrexone; Substance Withdrawal Syndrome; Substance-Related Disorders | 2017 |
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Topics: Acamprosate; Alcoholism; Baclofen; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate; Treatment Outcome | 2018 |
Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction.
Topics: Alcohol Deterrents; Alcoholism; Animals; Aripiprazole; Baclofen; Cyclopentanes; Gabapentin; Humans; Naltrexone; Quetiapine Fumarate | 2018 |
Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
Topics: Acamprosate; Alcoholism; Antidepressive Agents; Baclofen; Cholinergic Agonists; Disulfiram; Gabapentin; Humans; Naltrexone; Ondansetron; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Safety of nalmefene for the treatment of alcohol use disorder: an update.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Drug Approval; Humans; Naltrexone; Narcotic Antagonists | 2020 |
Opioid Withdrawal Precipitated by Long-Acting Antagonists.
Topics: Drug Combinations; Emergency Service, Hospital; Humans; Morphine; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2020 |
[Pharmacological profile and clinical findings of nalmefene (Selincro
Topics: Alcohol Drinking; Alcoholism; Animals; Clinical Trials, Phase III as Topic; Humans; Japan; Multicenter Studies as Topic; Naltrexone; Randomized Controlled Trials as Topic; Rats; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2020 |
[Treatment of borderline personality disorder with opioid antagonists: buprenorphine, nalmefene, naloxone and naltrexone in the treatment of dissociative symptoms, self-mutilation and suicidal behavior].
Topics: Borderline Personality Disorder; Buprenorphine; Dissociative Disorders; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Observational Studies as Topic; Self Mutilation; Suicidal Ideation | 2020 |
79 trial(s) available for naltrexone and nalmefene
| Article | Year |
|---|---|
Lower pleasantness of palatable foods in nalmefene-treated human volunteers.
Topics: Adult; Appetite; Appetite Depressants; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Double-Blind Method; Eating; Energy Intake; Humans; Hunger; Male; Naltrexone; Random Allocation; Satiation; Smell; Taste; Thirst | 1991 |
Human pharmacology and abuse potential of nalmefene.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Male; Morphine; Naltrexone; Narcotic Antagonists; Substance-Related Disorders | 1991 |
Duration of antagonistic effects of nalmefene and naloxone in opiate-induced sedation for emergency department procedures.
Topics: Adolescent; Adult; Aged; Attention; Consciousness; Double-Blind Method; Emergency Service, Hospital; Female; Humans; Male; Meperidine; Middle Aged; Multicenter Studies as Topic; Naloxone; Naltrexone; Random Allocation | 1989 |
Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis.
Topics: Chronic Disease; Dermatitis, Atopic; Double-Blind Method; Humans; Naltrexone; Narcotic Antagonists; Placebos; Pruritus; Random Allocation; Urticaria | 1989 |
Opiates, sleep and itch.
Topics: Adult; Aged; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Naltrexone; Pruritus; Sleep Wake Disorders | 1988 |
Antagonism of morphine-induced respiratory depression with nalmefene.
Topics: Adult; Carbon Dioxide; Depression, Chemical; Humans; Male; Middle Aged; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Partial Pressure; Respiration; Time Factors | 1988 |
Opioid peptides and primary biliary cirrhosis.
Topics: Adult; Aged; Bilirubin; Fatigue; Female; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pruritus; Substance Withdrawal Syndrome | 1988 |
The effects of nalmefene, a potent oral opiate antagonist, on exercise-induced bronchospasm.
Topics: Administration, Oral; Adolescent; Adult; Asthma; Asthma, Exercise-Induced; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Naltrexone; Narcotic Antagonists; Random Allocation | 1988 |
Prolonged blockade of opioid effect with oral nalmefene.
Topics: Administration, Oral; Adult; Analgesia; Clinical Trials as Topic; Double-Blind Method; Fentanyl; Humans; Male; Naltrexone; Narcotic Antagonists; Respiration; Time Factors | 1986 |
Reduction of hyperinsulinemia and insulin resistance by opiate receptor blockade in the polycystic ovary syndrome with acanthosis nigricans.
Topics: Acanthosis Nigricans; Adolescent; Adult; Blood Glucose; Female; Humans; Insulin; Insulin Resistance; Naloxone; Naltrexone; Narcotic Antagonists; Polycystic Ovary Syndrome | 1987 |
Failure of nalmefene and estrogen to improve memory in Alzheimer's disease.
Topics: Alzheimer Disease; Clinical Trials as Topic; Estradiol; Female; Humans; Memory; Memory Disorders; Naltrexone | 1987 |
Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist.
Topics: Administration, Oral; Adult; Appetite Depressants; Humans; Male; Naltrexone | 1987 |
Nalmefene: intravenous safety and kinetics of a new opioid antagonist.
Topics: Adult; Chromatography, High Pressure Liquid; Dizziness; Double-Blind Method; Drug Evaluation; Half-Life; Humans; Injections, Intravenous; Kinetics; Male; Middle Aged; Naltrexone; Radioimmunoassay | 1986 |
Prolonged antagonism of opioid action with intravenous nalmefene in man.
Topics: Adult; Drug Interactions; Fentanyl; Humans; Male; Muscle Rigidity; Naltrexone; Pain; Respiration; Tidal Volume; Time Factors | 1986 |
Effect of oral nalmefene, an opiate-receptor antagonist, on meal-stimulated gastric acid secretion and serum gastrin concentration in man.
Topics: Adult; Appetite Depressants; Eating; Female; Gastric Acid; Gastric Juice; Gastrins; Humans; Kinetics; Male; Naltrexone; Placebos; Time Factors | 1985 |
A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.
Topics: Alcoholism; Body Weight; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Naltrexone; Narcotic Antagonists; Patient Admission; Pilot Projects; Treatment Outcome | 1994 |
Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject.
Topics: Adult; Alanine Transaminase; Alcoholism; Aspartate Aminotransferases; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Liver Function Tests; Naltrexone; Narcotic Antagonists | 1994 |
Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Hydrocortisone; Male; Methoxyhydroxyphenylglycol; Naltrexone; Narcotic Antagonists; Prolactin; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 1993 |
Comparison of potency and duration of action of nalmefene and naloxone.
Topics: Adult; Double-Blind Method; Humans; Male; Naloxone; Naltrexone; Narcotic Antagonists; Reference Values; Time Factors | 1994 |
Nalmefene in the treatment of interstitial cystitis.
Topics: Adult; Aged; Aged, 80 and over; Cystitis; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 1994 |
Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study.
Topics: Adolescent; Adult; Drug Overdose; Emergency Service, Hospital; Female; Humans; Injections, Intravenous; Male; Naltrexone; Narcotic Antagonists; Narcotics; Pilot Projects; Prospective Studies; Treatment Outcome | 1993 |
Nalmefene enhances LH secretion in a proportion of oligo-amenorrheic athletes.
Topics: Adult; Amenorrhea; Analysis of Variance; Androstenedione; Dehydroepiandrosterone; Estradiol; Female; Humans; Luteinizing Hormone; Menstruation; Naltrexone; Narcotic Antagonists; Oligomenorrhea; Physical Education and Training; Pituitary Gland; Progesterone; Sports; Substance Withdrawal Syndrome; Thyrotropin; Thyroxine; Time Factors; Vagina | 1993 |
Assessment of nalmefene glucuronide as a selective gut opioid antagonist.
Topics: Adult; Arousal; Autonomic Nervous System; Constipation; Dose-Response Relationship, Drug; Gastrointestinal Motility; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists; Neurologic Examination; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1995 |
Current strategies for the treatment of alcohol dependence in the United States.
Topics: Alcoholics Anonymous; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome; United States | 1995 |
The effect of age on the pharmacokinetics of the opioid antagonist nalmefene.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Humans; Middle Aged; Naltrexone; Narcotic Antagonists | 1996 |
Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system.
Topics: Adult; Analgesics, Opioid; Brain; Carbon Radioisotopes; Cross-Over Studies; Female; Fentanyl; Humans; Male; Naloxone; Naltrexone; Narcotic Antagonists; Receptors, Opioid; Time Factors; Tomography, Emission-Computed | 1997 |
Open-label trial of oral nalmefene therapy for the pruritus of cholestasis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Cholestasis; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Pruritus | 1998 |
Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions.
Topics: Adult; Anesthetics, Dissociative; Anorexia; Chronic Disease; Compulsive Personality Disorder; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Ketamine; Memory; Naltrexone; Narcotic Antagonists; Treatment Outcome | 1998 |
Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Cocaine-Related Disorders; Dose-Response Relationship, Drug; Dynorphins; Female; Humans; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Peptide Fragments; Prolactin; Receptors, Dopamine; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu; Sex Characteristics; Time Factors | 1999 |
Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia.
Topics: Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Morphine; Naltrexone; Narcotic Antagonists; Nausea; Postoperative Complications; Pruritus; Vomiting | 1999 |
Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose.
Topics: Adult; Double-Blind Method; Drug Overdose; Emergency Treatment; Humans; Injections, Intravenous; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Neurologic Examination; Respiration; Time Factors; Treatment Outcome | 1999 |
A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
Topics: Administration, Oral; Alcohol Drinking; Alcoholism; Breath Tests; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ethanol; Humans; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Temperance; Treatment Outcome | 1999 |
Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study.
Topics: Administration, Oral; Adult; Antipruritics; Cholestasis; Double-Blind Method; Humans; Naltrexone; Narcotic Antagonists; Pain Measurement; Pruritus; Tablets; Time Factors | 1999 |
Rapid opioid detoxification during general anesthesia: a review of 20 patients.
Topics: Adult; Anesthesia, General; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Monitoring, Physiologic; Naloxone; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Substance Withdrawal Syndrome | 1999 |
Maximum tolerated dose of nalmefene in patients receiving epidural fentanyl and dilute bupivacaine for postoperative analgesia.
Topics: Adult; Aged; Analgesia, Epidural; Analgesics, Opioid; Anesthetics, Local; Bupivacaine; Female; Fentanyl; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pain, Postoperative | 2000 |
Drinking in alcoholics following an alcohol challenge research protocol.
Topics: Adult; Alcohol Drinking; Alcoholism; Female; Humans; Male; Middle Aged; Motivation; Naltrexone; Narcotic Antagonists; Research; Temperance | 2000 |
Nalmefene: blockade of intravenous morphine challenge effects in opioid abusing humans.
Topics: Adult; Analysis of Variance; Cross-Over Studies; Double-Blind Method; Humans; Injections, Intravenous; Male; Morphine; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Pupil | 2000 |
Cervene (Nalmefene) in acute ischemic stroke : final results of a phase III efficacy study. The Cervene Stroke Study Investigators.
Topics: Acute Disease; Aged; Aged, 80 and over; Brain Ischemia; Dose-Response Relationship, Drug; Double-Blind Method; Dynorphins; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Neuroprotective Agents; Receptors, Opioid, kappa; Risk Factors; Survival Analysis; Treatment Failure | 2000 |
Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study.
Topics: Analgesia, Epidural; Bayes Theorem; Child; Child, Preschool; Double-Blind Method; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Narcotics | 2000 |
Nalmefene for elective reversal of procedural sedation in children.
Topics: Analgesics, Opioid; Anesthetics, Intravenous; Antidotes; Child; Child, Preschool; Emergency Medical Services; Female; Fentanyl; Humans; Infant; Male; Midazolam; Naltrexone; Narcotic Antagonists | 2001 |
The impact of nalmefene on side effects due to intrathecal morphine at cesarean section.
Topics: Adult; Analgesia, Epidural; Analgesics, Opioid; Cesarean Section; Double-Blind Method; Female; Humans; Morphine; Naltrexone; Narcotic Antagonists; Pain, Postoperative; Postoperative Complications; Postoperative Nausea and Vomiting; Pregnancy; Pruritus; Statistics, Nonparametric; Survival Analysis; Time Factors | 2001 |
The use of nalmefene for intrathecal opioid-associated nausea in postpartum patients.
Topics: Adult; Analgesia, Obstetrical; Analgesics, Opioid; Double-Blind Method; Female; Humans; Injections, Spinal; Naltrexone; Narcotic Antagonists; Postoperative Nausea and Vomiting; Postpartum Period | 2002 |
A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Analysis of Variance; Environment; Female; Humans; Male; Middle Aged; Naltrexone | 2003 |
A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence.
Topics: Adult; Alcoholism; Analysis of Variance; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone | 2004 |
Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers.
Topics: Adult; Aged; Alcohol Drinking; Alcoholism; Analysis of Variance; Behavior, Addictive; Female; Humans; Male; Middle Aged; Naltrexone | 2004 |
Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.
Topics: Adolescent; Adult; Analgesics, Opioid; Area Under Curve; Caudate Nucleus; Electrocardiography; Fentanyl; Glucuronides; Humans; Male; Naltrexone; Narcotic Antagonists; Positron-Emission Tomography; Prefrontal Cortex; Receptors, Opioid, mu; Thalamus | 2005 |
Unexpected placebo response in premenstrual dysphoric disorder: implication of endogenous opioids.
Topics: beta-Endorphin; Double-Blind Method; Female; Humans; Mood Disorders; Naltrexone; Opioid Peptides; Pilot Projects; Placebo Effect; Premenstrual Syndrome; Surveys and Questionnaires | 2005 |
Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling.
Topics: Adult; Age of Onset; Ambulatory Care; Behavior, Addictive; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drugs, Investigational; Female; Gambling; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Placebos; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome | 2006 |
Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
Topics: Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Finland; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Patient Compliance; Placebos; Sleep Initiation and Maintenance Disorders; Substance Abuse Treatment Centers; Temperance; Treatment Outcome | 2007 |
Predicting response to opiate antagonists and placebo in the treatment of pathological gambling.
Topics: Adult; Age Factors; Aged; Alcoholism; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gambling; Humans; Logistic Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Predictive Value of Tests; Psychometrics; Severity of Illness Index; Treatment Outcome; Young Adult | 2008 |
[Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers].
Topics: Adult; China; Female; Humans; Injections, Intravenous; Male; Naltrexone; Narcotic Antagonists | 2008 |
The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study.
Topics: Disruptive, Impulse Control, and Conduct Disorders; Follow-Up Studies; Gambling; Humans; Naltrexone; Narcotic Antagonists; Obsessive-Compulsive Disorder; Personality Inventory; Psychometrics; Reproducibility of Results | 2009 |
[Clinical observation of the effect of nalmefene in treatment of septic shock].
Topics: Adult; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Prospective Studies; Shock, Septic; Treatment Outcome | 2010 |
Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gambling; Humans; Intention to Treat Analysis; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Placebos; Treatment Outcome; United States; Young Adult | 2010 |
[Serum NT-proBNP levels in neonates with severe asphyxia and the effects of nalmefene on the NT-proBNP levels].
Topics: Asphyxia Neonatorum; Creatine Kinase, MB Form; Female; Humans; Infant, Newborn; Male; Naltrexone; Natriuretic Peptide, Brain; Peptide Fragments | 2010 |
Trial watch: Nalmefene reduces alcohol use in phase III trial.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2011 |
A randomized, double-blind, vehicle-controlled crossover study to determine the anti-pruritic efficacy, safety and local dermal tolerability of a topical formulation (srd174 cream) of the long-acting opiod antagonist nalmefene in subjects with atopic derm
Topics: Administration, Cutaneous; Administration, Topical; Adult; Antipruritics; Cross-Over Studies; Delayed-Action Preparations; Dermatitis, Atopic; Double-Blind Method; Drug Evaluation; Electronic Health Records; Emollients; Female; Humans; Intention to Treat Analysis; Male; Naltrexone; Narcotic Antagonists; Pruritus; Receptors, Opioid; Treatment Outcome | 2011 |
Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Topics: Adult; Anti-Infective Agents; Arrhythmias, Cardiac; Aza Compounds; Biomarkers, Pharmacological; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Guidelines as Topic; Heart Rate; Humans; Long QT Syndrome; Male; Moxifloxacin; Naltrexone; Narcotic Antagonists; Placebos; Prospective Studies; Quinolines; Treatment Outcome; Young Adult | 2011 |
Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
Topics: Alanine Transaminase; Alcohol Drinking; Alcoholism; Double-Blind Method; Drug Administration Schedule; Female; gamma-Glutamyltransferase; Humans; Liver; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Secondary Prevention | 2013 |
A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2013 |
Can alcohol dependent patients adhere to an 'as-needed' medication regimen?
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Medication Adherence; Middle Aged; Naltrexone; Narcotic Antagonists; Self Care; Treatment Outcome | 2014 |
Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Young Adult | 2014 |
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model.
Topics: Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged; Naltrexone; Public Health; Risk Assessment; Social Support | 2014 |
Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Harm Reduction; Humans; Logistic Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2015 |
Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: a preliminary report.
Topics: Adult; Alcoholism; Borderline Personality Disorder; Comorbidity; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Research Report | 2017 |
Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.
Topics: Administration, Intravenous; Adult; Alcoholism; Anticipation, Psychological; Corpus Striatum; Double-Blind Method; Drug Synergism; Ethanol; Functional Neuroimaging; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Reward | 2017 |
Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.
Topics: Adult; Alcohol Drinking; Alcoholism; Ambulatory Care; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outpatients; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2018 |
A comparison between phase-III trials and a phase-IV study of nalmefene in alcohol use disorder patients. Is there a difference?
Topics: Adult; Alcoholism; Behavior, Addictive; Comorbidity; Female; Humans; Male; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists; Risk | 2019 |
Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care.
Topics: Adult; Alcoholism; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Naltrexone; Neuroprotective Agents; Primary Health Care; Psychotherapy; Treatment Outcome; Young Adult | 2018 |
Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.
Topics: Administration, Intranasal; Adolescent; Adult; Analgesics, Opioid; Cross-Over Studies; Double-Blind Method; Drug Development; Drug Overdose; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Synthetic Drugs; Treatment Outcome; Young Adult | 2019 |
Nalmefene in alcohol-dependent patients with a high drinking risk: Randomized controlled trial.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Double-Blind Method; Endpoint Determination; Female; Humans; Male; Middle Aged; Naltrexone; Risk; Treatment Outcome | 2019 |
Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis.
Topics: Alcohol Drinking; Alcoholism; Elasticity; Elasticity Imaging Techniques; Fatty Liver; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2020 |
The effects of nalmefene on emotion processing in alcohol use disorder - A randomized, controlled fMRI study.
Topics: Adult; Aged; Alcoholism; Cross-Over Studies; Double-Blind Method; Emotions; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Photic Stimulation; Psychomotor Performance; Treatment Outcome | 2019 |
Neuroendocrine effects of naltrexone versus nalmefene in humans.
Topics: Administration, Intravenous; Adrenocorticotropic Hormone; Adult; Affect; Female; Humans; Hydrocortisone; Male; Naltrexone; Narcotic Antagonists; Prolactin | 2020 |
Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Time Factors | 2020 |
Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder.
Topics: Adult; Alcoholism; Craving; Cross-Over Studies; Cues; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Photic Stimulation; Prospective Studies; Ventral Striatum; Young Adult | 2021 |
Naloxone and nalmefene absorption delivered by hollow microneedles compared to intramuscular injection.
Topics: Analgesics, Opioid; Animals; Cross-Over Studies; Dogs; Humans; Injections, Intramuscular; Naloxone; Naltrexone; Narcotic Antagonists | 2022 |
Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: An exploratory analysis.
Topics: Alcohol Drinking; Alcoholism; Ethanol; Humans; Naltrexone; Narcotic Antagonists | 2022 |
The effects of nalmefene on the impulsive and reflective system in alcohol use disorder: A resting-state fMRI study.
Topics: Alcoholism; Brain Mapping; Cross-Over Studies; Female; Humans; Magnetic Resonance Imaging; Naltrexone | 2022 |
205 other study(ies) available for naltrexone and nalmefene
| Article | Year |
|---|---|
3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity.
Topics: Analgesia; Animals; Appetite Depressants; Cyclohexanes; Diuresis; Eating; Endorphins; Guinea Pigs; Male; Mice; Molecular Structure; Piperidines; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Structure-Activity Relationship | 1993 |
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
Topics: Animals; Aorta, Thoracic; Cocaine; Cyclic AMP; Electric Stimulation; Guinea Pigs; Humans; Ileum; In Vitro Techniques; Male; Mice; Muscle, Smooth; Opioid-Related Disorders; Rats; Receptors, Dopamine; Receptors, Opioid; Receptors, Serotonin; Substance-Related Disorders | 1998 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
Topics: Alcohol Drinking; Alcoholism; Amides; Animals; Binding, Competitive; Drug Evaluation, Preclinical; Ethanol; Humans; Hydrogen Bonding; Liver; Mice; Microsomes, Liver; Molecular Structure; Morphinans; Naltrexone; Rats; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Stereoisomerism; Structure-Activity Relationship | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
Topics: Amides; Analgesics, Opioid; Humans; Protein Binding; Receptors, Opioid; Structure-Activity Relationship; Tramadol | 2009 |
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
Topics: Alcohol Deterrents; Alcoholism; Animals; Humans; Liver; Male; Mice; Naltrexone; Nociceptin Receptor; Protein Binding; Rats; Rats, Wistar; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Structure-Activity Relationship | 2009 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Effects of naloxone and nalmefene in rat spinal cord injury induced by the ventral compression technique.
Topics: Animals; Drug Evaluation, Preclinical; Intervertebral Disc Displacement; Naloxone; Naltrexone; Nerve Crush; Paralysis; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, kappa; Spinal Cord Injuries; Spinal Fractures | 1992 |
Ex vivo determination of opiate antagonist binding at mu-opioid ([3H]-DAGO) receptors in hypothalamic micropunches from maturing female rats: comparison between SDZ 210-096 and nalmefene.
Topics: Age Factors; Animals; Animals, Newborn; Binding, Competitive; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Female; Hypothalamus; Morphinans; Naltrexone; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, mu; Sexual Maturation; Vagina | 1992 |
The pruritus of cholestasis and the opioid system.
Topics: Cholangitis, Sclerosing; Female; Humans; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Pruritus; Receptors, Opioid | 1992 |
Involvement of opioid receptors in nucleus tractus solitarii in modulating endotoxic hypotension in rats.
Topics: Animals; Blood Pressure; Endotoxins; Heart Rate; Hypotension; Male; Medulla Oblongata; Microinjections; Naltrexone; Narcotic Antagonists; Neurons, Afferent; Rats; Rats, Wistar; Receptors, Opioid; Stereotaxic Techniques | 1992 |
Progesterone inhibits the estrogen-induced gonadotropin surge in the rhesus monkey independent of endogenous opiates.
Topics: Analysis of Variance; Animals; Estradiol; Estrogen Antagonists; Feedback; Female; Follicle Stimulating Hormone; Follicular Phase; Luteal Phase; Luteinizing Hormone; Macaca mulatta; Multivariate Analysis; Naltrexone; Narcotic Antagonists; Progesterone; Radioimmunoassay; Reference Values; Silicone Elastomers | 1992 |
Evaluation of the sites of opioid influence on anterior pituitary hormone secretion using a quaternary opiate antagonist.
Topics: Analgesia; Animals; Brain Mapping; Male; Morphine; Naltrexone; Narcotic Antagonists; Neurons; Pain Measurement; Pituitary Hormones, Anterior; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, mu | 1991 |
Comparison of a serotonin antagonist, opioid antagonist, and TRH analog for the acute treatment of experimental spinal trauma.
Topics: Animals; Azetidines; Dipeptides; Evoked Potentials, Somatosensory; Male; Mianserin; Naltrexone; Narcotic Antagonists; Prognosis; Rats; Rats, Inbred Strains; Spinal Cord; Spinal Cord Injuries; Thyrotropin-Releasing Hormone | 1991 |
Role of opioid antagonists in the rat liver ischemia model.
Topics: Animals; Calcium Channel Blockers; Hepatic Artery; Ischemia; Liver; Nalbuphine; Naloxone; Naltrexone; Narcotic Antagonists; Portal Vein; Rats; Rats, Inbred Strains; Verapamil | 1991 |
Protective effect of nalmefene and naloxone on the ischemically damaged small bowel.
Topics: Animals; Intestine, Small; Ischemia; Mesenteric Arteries; Naloxone; Naltrexone; Narcotic Antagonists; Necrosis; Rats; Rats, Inbred Strains; Time Factors | 1991 |
Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors.
Topics: Animals; Binding, Competitive; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, Leucine-2-Alanine; Enkephalins; Food Deprivation; Guinea Pigs; Injections, Intraventricular; Male; Mice; Morphine; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Reaction Time; Reinforcement Schedule | 1990 |
Dynorphin A-(1-17) induces alterations in free fatty acids, excitatory amino acids, and motor function through an opiate-receptor-mediated mechanism.
Topics: Amino Acids; Animals; Dose-Response Relationship, Drug; Drosophila Proteins; Dynorphins; Fatty Acids, Nonesterified; Injections, Spinal; Male; Membrane Proteins; Motor Activity; Naltrexone; Nerve Tissue Proteins; Peptide Fragments; Rats; Rats, Inbred Strains; Receptors, Opioid; Receptors, Opioid, kappa; Spinal Cord; Spinal Cord Injuries; Stereoisomerism | 1990 |
Effects of opioid blockade with nalmefene in older impotent men.
Topics: Erectile Dysfunction; Feeding Behavior; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Luteinizing Hormone; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Penis; Testosterone | 1990 |
Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK-801 and the opiate-receptor antagonist nalmefene in experimental spinal cord ischemia.
Topics: Animals; Aspartic Acid; Dibenzocycloheptenes; Dizocilpine Maleate; Humans; Ischemia; Male; N-Methylaspartate; Naltrexone; Narcotic Antagonists; Rabbits; Spinal Cord; Time Factors | 1990 |
Nalmefene and pruritus.
Topics: Humans; Naltrexone; Pruritus; Random Allocation | 1990 |
Opiate antagonist nalmefene improves intracellular free Mg2+, bioenergetic state, and neurologic outcome following traumatic brain injury in rats.
Topics: Adenosine Triphosphate; Animals; Blood Pressure; Brain Injuries; Disease Models, Animal; Energy Metabolism; Magnesium; Magnetic Resonance Spectroscopy; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Phosphates; Phosphocreatine; Phosphorus; Rats; Rats, Inbred Strains | 1990 |
Opiate-receptor antagonist improves metabolic recovery and limits neurochemical alterations associated with reperfusion after global brain ischemia in rats.
Topics: Adenosine Triphosphate; Amino Acids; Animals; Brain Chemistry; Brain Ischemia; Fatty Acids, Nonesterified; Lactates; Lactic Acid; Magnetic Resonance Spectroscopy; Male; Naltrexone; Narcotic Antagonists; Rats; Reperfusion | 1990 |
Actions of the opioid antagonist, nalmefene, and congeners on reperfusion cardiac arrhythmias and regional left coronary blood flow.
Topics: Animals; Arrhythmias, Cardiac; Coronary Circulation; Dogs; Female; Injections, Intravenous; Male; Myocardial Reperfusion; Naltrexone; Narcotic Antagonists; Premedication; Time Factors; Ventricular Function, Left | 1990 |
Effects of nalmefene on feeding in humans. Dissociation of hunger and palatability.
Topics: Adolescent; Adult; Affect; Appetite Depressants; Cognition; Dose-Response Relationship, Drug; Humans; Hunger; Male; Middle Aged; Naltrexone; Psychomotor Performance; Reaction Time; Salivation; Taste | 1990 |
Naloxone antagonism of corticotropin-releasing hormone stimulation of prolactin secretion in rhesus monkeys.
Topics: Animals; Corticotropin-Releasing Hormone; Dose-Response Relationship, Drug; Drug Synergism; Female; Macaca mulatta; Naloxone; Naltrexone; Narcotic Antagonists; Ovariectomy; Prolactin; Receptors, Opioid; Time Factors | 1989 |
Pharmacological characterization of supersensitivity to naltrexone in squirrel monkeys.
Topics: Animals; Azocines; Behavior, Animal; Benzomorphans; Diprenorphine; Drug Administration Schedule; Morphine; Naloxone; Naltrexone; Receptors, Opioid; Saimiri | 1989 |
A dose run-up and safety evaluation of nalmefene HCl in human volunteers.
Topics: Adult; Arousal; Dose-Response Relationship, Drug; Humans; Male; Morphine Dependence; Naltrexone; Narcotic Antagonists | 1989 |
The implication of opiates in the glucocorticoid-mediated inhibition of LH secretion in rats.
Topics: Animals; Corticosterone; Dexamethasone; Luteinizing Hormone; Male; Naloxone; Naltrexone; Narcotic Antagonists; Orchiectomy; Pituitary Hormone-Releasing Hormones; Rats; Rats, Inbred Strains; Stimulation, Chemical | 1989 |
Comparison of the duration of action of nalmefene and naloxone on the hypothalamic-pituitary axis of the rhesus monkey.
Topics: Animals; Female; Hypothalamo-Hypophyseal System; Luteinizing Hormone; Macaca mulatta; Naloxone; Naltrexone; Prolactin; Time Factors | 1989 |
Isolation of a novel morphinan 3-O-diglucuronide metabolite from dog urine.
Topics: Animals; Chromatography, High Pressure Liquid; Dogs; Magnetic Resonance Spectroscopy; Naltrexone; Protein Conformation | 1989 |
Opioid modulation of feeding and drinking in fowls.
Topics: Animals; Chickens; Drinking; Eating; Enkephalin, Methionine; Female; Injections, Intramuscular; Injections, Intravenous; Injections, Intraventricular; Naloxone; Naltrexone; Time Factors | 1989 |
An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice.
Topics: Amphetamine; Animals; Appetite Depressants; Body Weight; Calcitonin; Dextroamphetamine; Drug Tolerance; Eating; Fluoxetine; Mice; Morphine; Naltrexone; Neurotransmitter Agents | 1987 |
Pro-opiomelanocortin-derived peptides in the testis: evidence for a possible role in Leydig and Sertoli cell function.
Topics: Animals; beta-Endorphin; Castration; Cell Differentiation; Chromatography, High Pressure Liquid; Endorphins; Hypophysectomy; Leydig Cells; Male; Naloxone; Naltrexone; Pro-Opiomelanocortin; Progesterone; Rats; Rats, Inbred Strains; RNA, Messenger | 1986 |
Influence of nalmefene on energy balance and glucose regulation in Zucker rats.
Topics: Administration, Oral; Animals; beta-Endorphin; Blood Glucose; Endorphins; Energy Metabolism; Feeding Behavior; Female; Injections, Subcutaneous; Insulin; Male; Naltrexone; Narcotic Antagonists; Obesity; Rats; Rats, Zucker; Tolbutamide | 1986 |
Binding of a new opiate antagonist, nalmefene, to rat brain membranes.
Topics: Animals; Binding, Competitive; Brain; In Vitro Techniques; Kinetics; Membranes; Naloxone; Naltrexone; Rats; Receptors, Opioid; Receptors, Opioid, mu | 1985 |
The role of endogenous opioids in congestive heart failure: effects of nalmefene on systemic and regional hemodynamics in dogs.
Topics: Adrenocorticotropic Hormone; Animals; beta-Endorphin; Dogs; Endorphins; Heart Failure; Hemodynamics; Hydrocortisone; Naltrexone; Prazosin; Propranolol; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Receptors, Opioid; Sympathetic Nervous System | 1987 |
Opiate antagonist nalmefene inhibits ethanol-induced flushing in Asians: a preliminary study.
Topics: Acetaldehyde; Adult; Alcohol Drinking; Asian; Blood Pressure; Body Temperature Regulation; Endorphins; Ethanol; Flushing; Heart Rate; Humans; Hydrocortisone; Male; Naltrexone; Narcotic Antagonists | 1988 |
Use of narcotic antagonists to modify stereotypic self-licking, self-chewing, and scratching behavior in dogs.
Topics: Animals; Behavior, Animal; Dog Diseases; Dogs; Injections, Subcutaneous; Naltrexone; Narcotic Antagonists; Pruritus | 1988 |
Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates.
Topics: Animals; Colon; Constipation; Diarrhea; Dose-Response Relationship, Drug; Glucuronates; Male; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Skin Temperature; Substance-Related Disorders | 1988 |
Opioidergic modulation of the oestradiol-induced LH surge in the rat: roles of ovarian steroids.
Topics: Animals; Diestrus; Estradiol; Female; Luteinizing Hormone; Naloxone; Naltrexone; Ovariectomy; Proestrus; Progesterone; Rats; Rats, Inbred Strains | 1988 |
Effect of morphine and nalmefene on energy balance in diabetic and non-diabetic rats.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Eating; Energy Metabolism; Male; Morphine; Naltrexone; Rats; Rats, Inbred Strains | 1988 |
Opiate-receptor antagonist nalmefene improves neurological recovery after traumatic spinal cord injury in rats through a central mechanism.
Topics: Animals; Dose-Response Relationship, Drug; Injections, Intravenous; Injections, Spinal; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Spinal Cord; Spinal Cord Injuries | 1988 |
Regional brain glucose uptake in genetically diabetic C57BL/KsJ mice: modulation by the opiate antagonist, nalmefene.
Topics: Animals; Brain; Deoxy Sugars; Deoxyglucose; Diabetes Mellitus, Experimental; Female; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Naltrexone; Narcotic Antagonists; Organ Specificity; Reference Values | 1988 |
Induction of LH hypersecretion in cyclic rats during the afternoon of oestrus by oestrogen in conjunction with progesterone antagonism or opioidergic blockade.
Topics: Animals; Estradiol; Estrenes; Estrus; Female; Luteinizing Hormone; Mifepristone; Naltrexone; Narcotic Antagonists; Proestrus; Progesterone; Progestins; Rats; Rats, Inbred Strains; Secretory Rate; Stimulation, Chemical | 1988 |
Use of a narcotic antagonist (nalmefene) to suppress self-mutilative behavior in a stallion.
Topics: Animals; Dose-Response Relationship, Drug; Horse Diseases; Horses; Male; Naltrexone; Narcotic Antagonists; Self Mutilation; Videotape Recording | 1988 |
Antagonism by nalmefene of systemic and intrathecal morphine-induced analgesia in mice.
Topics: Analgesia; Animals; Injections, Intravenous; Injections, Spinal; Male; Mice; Morphine; Naloxone; Naltrexone; Time Factors | 1987 |
Antagonism of endogenous opioids modulates memory processing.
Topics: Animals; Anisomycin; Avoidance Learning; Dose-Response Relationship, Drug; Electroshock; Endorphins; Learning; Male; Memory; Mice; Naloxone; Naltrexone; Scopolamine | 1987 |
A panic attack precipitated by opiate blockade--a case study.
Topics: Adult; Anorexia Nervosa; Anxiety Disorders; Fear; Female; Humans; Naltrexone; Panic | 1987 |
Immobilization of white-tailed deer by etorphine and xylazine and its antagonism by nalmefene and yohimbine.
Topics: Anesthesia, General; Anesthesia, Intravenous; Animals; Deer; Etorphine; Female; Immobilization; Injections, Intramuscular; Male; Morphinans; Naltrexone; Thiazines; Xylazine; Yohimbine | 1987 |
The effects of opioid receptor antagonists suggest that testicular opiates regulate Sertoli and Leydig cell function in the neonatal rat.
Topics: Androgen-Binding Protein; Animals; Animals, Newborn; Dose-Response Relationship, Drug; Endorphins; Hypertrophy; Leydig Cells; Male; Naloxone; Naltrexone; Orchiectomy; Rats; Rats, Inbred Strains; Sertoli Cells; Testis; Testosterone | 1986 |
Investigation into the use of narcotic antagonists in the treatment of a stereotypic behavior pattern (crib-biting) in the horse.
Topics: Animals; Behavior, Animal; Female; Horses; Male; Naloxone; Naltrexone; Narcotic Antagonists | 1987 |
Unexpected effects of nalmefene, a new opiate antagonist, on the hypothalamic-pituitary-gonadal axis in the male rat.
Topics: Animals; Dose-Response Relationship, Drug; Feedback; Hypothalamo-Hypophyseal System; Luteinizing Hormone; Male; Naloxone; Naltrexone; Rats; Testosterone; Time Factors | 1985 |
Nalmefene: radioimmunoassay for a new opioid antagonist.
Topics: Humans; Kinetics; Naloxone; Naltrexone; Narcotic Antagonists; Radioimmunoassay | 1984 |
A rapid, quantitative in vivo assay for narcotic antagonists.
Topics: Animals; Dose-Response Relationship, Drug; Female; Humans; Morphine Dependence; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Skin Temperature; Tail; Time Factors | 1984 |
Do testicular opiates regulate Leydig cell function?
Topics: Androgen-Binding Protein; Animals; Chorionic Gonadotropin; Endorphins; Epididymis; Leydig Cells; Male; Naloxone; Naltrexone; Organ Size; Rats; Rats, Inbred Strains; Testosterone | 1984 |
Nalmefene decreases meal size, food and water intake and weight gain in Zucker rats.
Topics: Animals; Appetite; Appetite Depressants; Body Weight; Drinking; Energy Intake; Female; Male; Naloxone; Naltrexone; Obesity; Rats; Rats, Zucker; Time Factors | 1983 |
Nalmefene: quantitation of a new narcotic antagonist in human plasma using high performance-liquid chromatography with electrochemical detection.
Topics: Chromatography, High Pressure Liquid; Electrochemistry; Humans; Kinetics; Morphinans; Naloxone; Naltrexone; Narcotic Antagonists; Time Factors | 1983 |
Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Gastrointestinal Transit; Guinea Pigs; Male; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Pyrrolidines; Receptors, Opioid, kappa; Receptors, Opioid, mu | 1995 |
Nalmefene--a long-acting injectable opioid antagonist.
Topics: Clinical Trials as Topic; Costs and Cost Analysis; Dose-Response Relationship, Drug; Drug Overdose; Humans; Injections, Intravenous; Kidney Failure, Chronic; Liver Diseases; Naltrexone; Narcotic Antagonists; Postoperative Care; Respiratory Insufficiency | 1995 |
Melatonin modifies prolactin release induced by opiate antagonists in male rats.
Topics: Animals; Injections, Subcutaneous; Male; Melatonin; Naloxone; Naltrexone; Narcotic Antagonists; Prolactin; Quaternary Ammonium Compounds; Rats; Rats, Wistar | 1995 |
Inhibiting a spinal dynorphin A component enhances intrathecal morphine antinociception in mice.
Topics: Analgesics; Animals; Cerebral Ventricles; Dynorphins; Injections, Spinal; Male; Mice; Mice, Inbred ICR; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Spine | 1993 |
Opioid receptor antagonist nalmefene stereospecifically inhibits glutamate release during global cerebral ischemia.
Topics: Animals; Aspartic Acid; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Glycine; Hippocampus; Ischemic Attack, Transient; Kinetics; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Reperfusion; Stereoisomerism; Taurine; Time Factors | 1993 |
Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys.
Topics: Alfentanil; Analgesics; Animals; Behavior, Animal; Benzofurans; Female; Macaca mulatta; Male; Molecular Structure; Nalbuphine; Naltrexone; Narcotic Antagonists; Pyrrolidines | 1994 |
A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder.
Topics: Adult; Aged; Combat Disorders; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Stress Disorders, Post-Traumatic | 1993 |
The effect of nalmefene on pulsatile secretion of luteinizing hormone and prolactin in men.
Topics: Adult; Endorphins; Humans; Luteinizing Hormone; Male; Naloxone; Naltrexone; Prolactin; Secretory Rate | 1993 |
Comparison of single and combination drug treatment strategies in experimental brain trauma.
Topics: Animals; Azetidines; Behavior, Animal; Brain Injuries; Dextrorphan; Dipeptides; Drug Therapy, Combination; Forelimb; Magnesium Sulfate; Male; Movement; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley | 1993 |
A comparison of YM-14673, U-50488H, and nalmefene after spinal cord injury in the rat.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Azetidines; Dipeptides; Female; Naltrexone; Narcotic Antagonists; Nervous System; Pyrrolidines; Rats; Rats, Sprague-Dawley; Spinal Cord Injuries | 1993 |
Influence of hyperkalaemia and ischaemia on non-receptor-mediated cardiac electrophysiological effects of naloxone.
Topics: Action Potentials; Animals; Culture Techniques; Dose-Response Relationship, Drug; Electrophysiology; Heart Conduction System; Hyperkalemia; Morphine; Myocardial Ischemia; Naloxone; Naltrexone; Narcotic Antagonists; Rabbits; Refractory Period, Electrophysiological | 1993 |
Determination of nalmefene in plasma by high-performance liquid chromatography with electrochemical detection and its application in pharmacokinetic studies.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Indicators and Reagents; Injections, Intravenous; Naltrexone; Narcotic Antagonists | 1993 |
Duration of opioid antagonism by nalmefene and naloxone in the dog: an integrated pharmacokinetic/pharmacodynamic comparison.
Topics: Animals; Blood Gas Monitoring, Transcutaneous; Dogs; Female; Fentanyl; Infusions, Intravenous; Models, Biological; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Respiration | 1995 |
Duration of opioid antagonism by nalmefene and naloxone in the dog. A nonparametric pharmacodynamic comparison based on generalized cross-validated spline estimation.
Topics: Analysis of Variance; Animals; Carbon Dioxide; Computer Simulation; Cross-Over Studies; Dogs; Drug Tolerance; Fentanyl; Injections, Intravenous; Male; Models, Statistical; Naloxone; Naltrexone; Narcotic Antagonists; Respiratory Insufficiency; Time Factors | 1995 |
Effects of melatonin in vivo upon luteinizing hormone and prolactin releases induced by opiate receptor antagonists in adult male rats.
Topics: Animals; Luteinizing Hormone; Male; Melatonin; Naloxone; Naltrexone; Narcotic Antagonists; Prolactin; Quaternary Ammonium Compounds; Rats; Rats, Wistar | 1996 |
Disposition of the opioid antagonist, nalmefene, in rat and dog.
Topics: Animals; Body Fluids; Chromatography, High Pressure Liquid; Dogs; Glucuronates; Kinetics; Male; Mass Spectrometry; Microsomes, Liver; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Species Specificity | 1996 |
The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Glucuronates; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Reference Values; Renal Dialysis | 1996 |
Stability of revex, nalmefene hydrochloride injection, in injectable solutions.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Drug Storage; Hydrogen-Ion Concentration; Injections, Intravenous; Naltrexone; Narcotic Antagonists; Solutions | 1996 |
International update: new findings on promising medications.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Clinical Trials as Topic; Cocaine; Comorbidity; Europe; Humans; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Taurine; United States | 1996 |
Acute pulmonary edema in a young male after intravenous nalmefene.
Topics: Acute Disease; Adult; Analgesics, Opioid; Anesthesia; Humans; Infusions, Intravenous; Male; Morphine; Naltrexone; Narcotic Antagonists; Pulmonary Edema | 1997 |
Potential danger of nalmefene use in the emergency department.
Topics: Emergency Service, Hospital; Heroin; Humans; Naltrexone; Narcotic Antagonists; Patient Discharge; Substance Withdrawal Syndrome | 1997 |
Effects of liver disease on the disposition of the opioid antagonist nalmefene.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Case-Control Studies; Female; Galactose; Glucuronates; Humans; Injections, Intravenous; Liver Diseases; Male; Matched-Pair Analysis; Middle Aged; Naltrexone; Narcotic Antagonists; Severity of Illness Index | 1997 |
Use of positron emission tomography to measure the effects of nalmefene on D1 and D2 dopamine receptors in rat brain.
Topics: Animals; Benzazepines; Brain Chemistry; Cerebral Cortex; Dopamine Agonists; Dopamine Antagonists; Male; Naltrexone; Narcotic Antagonists; Neostriatum; Pilot Projects; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Spiperone; Tomography, Emission-Computed | 1997 |
Nalmefene and the urine opiate screen.
Topics: Adult; Cross Reactions; Drug Evaluation, Preclinical; False Positive Reactions; Humans; Immunoassay; Molecular Structure; Morphine; Naltrexone; Narcotics | 1998 |
Effects of nalmefene, CG3703, tirilazad, or dopamine on cerebral blood flow, oxygen delivery, and electroencephalographic activity after traumatic brain injury and hemorrhage.
Topics: Animals; Antioxidants; Blood Gas Analysis; Blood Pressure; Brain Injuries; Cats; Cerebral Hemorrhage; Cerebrovascular Circulation; Dopamine; Electroencephalography; Female; Hemoglobins; Male; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Oxygen Consumption; Pregnatrienes; Thyrotropin-Releasing Hormone | 1997 |
Opioid antagonists in the treatment of impulse-control disorders.
Topics: Adult; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gambling; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists | 1998 |
New treatment options for substance abuse from a public health viewpoint.
Topics: Alcohol Deterrents; Alcoholism; Clinical Trials as Topic; Disulfiram; Extinction, Psychological; Humans; Naltrexone; Narcotic Antagonists | 1998 |
Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Alcoholism; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Infusions, Intravenous; Male; Middle Aged; Naloxone; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System; Treatment Outcome | 1998 |
Effect of naltrexone and its derivatives, nalmefene and naltrindole, on conditioned anticipatory behaviour and saccharin intake in rats.
Topics: Animals; Conditioning, Operant; Cues; Dose-Response Relationship, Drug; Drinking Behavior; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Saccharin; Sweetening Agents; Taste | 1997 |
The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Genotype; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains | 1998 |
Nalmefene. JF 1, nalmetrene, NIH 10365, ORF 11676, Arthrene, Cervene, Incystene, Revex.
Topics: Animals; Drug Overdose; Drugs, Investigational; Humans; Male; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Rabbits; Stroke | 1999 |
Nalmefene for alcohol dependence.
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2000 |
An experimental itch model in monkeys: characterization of intrathecal morphine-induced scratching and antinociception.
Topics: Analgesics, Opioid; Animals; Antipruritics; Dose-Response Relationship, Drug; Female; Hot Temperature; Injections, Spinal; Macaca mulatta; Male; Morphine; Naltrexone; Narcotic Antagonists; Pain; Pain Measurement; Pruritus; Receptors, Opioid | 2000 |
Acute effects of nalmefene on LH, prolactin, and testosterone in male rhesus monkeys.
Topics: Animals; Hypothalamus; Kinetics; Luteinizing Hormone; Macaca mulatta; Male; Naltrexone; Narcotic Antagonists; Pituitary Gland; Prolactin; Testosterone | 2000 |
Inhibition of passive cutaneous anaphylaxis-associated scratching behavior by mu-opioid receptor antagonists in ICR mice.
Topics: Animals; Behavior, Animal; Capillary Permeability; Female; Histamine; Humans; Mice; Mice, Inbred ICR; Naloxone; Naltrexone; Narcotic Antagonists; p-Methoxy-N-methylphenethylamine; Passive Cutaneous Anaphylaxis; Pruritus; Receptors, Opioid, mu | 2000 |
Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
Topics: Analgesics, Opioid; Animals; Benzylidene Compounds; Cell Line; Cell Membrane; Cyclic AMP; Dose-Response Relationship, Drug; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Kidney; Magnesium; Male; Mice; Mice, Inbred ICR; Morphine; Morphine Dependence; Naloxone; Naltrexone; Narcotic Antagonists; Nociceptors; Receptors, Opioid, mu; Signal Transduction; Substance Withdrawal Syndrome; Sulfur Radioisotopes; Transfection; Tritium | 2001 |
Rapid and sensitive determination of nalmefene in human plasma by gas chromatography-mass spectrometry.
Topics: Gas Chromatography-Mass Spectrometry; Naltrexone; Narcotic Antagonists; Reference Standards; Reproducibility of Results; Sensitivity and Specificity | 2002 |
Potentiation of the excitatory action of NMDA in ventrolateral periaqueductal gray by the mu-opioid receptor agonist, DAMGO.
Topics: Action Potentials; Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Drug Interactions; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, Methionine; Enzyme Inhibitors; Ethylmaleimide; Female; Male; N-Methylaspartate; Naltrexone; Narcotic Antagonists; Neural Inhibition; Neural Pathways; Neurons; Organ Culture Techniques; Periaqueductal Gray; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid, mu; Synaptic Transmission | 2002 |
Characterization of scratching responses in rats following centrally administered morphine or bombesin.
Topics: Analgesics, Opioid; Animals; Antipruritics; Bombesin; Brain; Dose-Response Relationship, Drug; Grooming; Injections, Intraventricular; Injections, Spinal; Male; Morphine; Naltrexone; Narcotic Antagonists; Premedication; Rats; Rats, Wistar; Receptors, Opioid, mu; Spinal Cord; Stereotyped Behavior | 2003 |
Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviors in alcohol-preferring (P) rats.
Topics: Animals; Behavior, Addictive; Brain; Central Nervous System Depressants; Conditioning, Operant; Dose-Response Relationship, Drug; Ethanol; Female; Functional Laterality; Microinjections; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Receptors, Opioid; Reinforcement, Psychology; Saccharin | 2004 |
Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice.
Topics: Animals; Appetite Regulation; Body Weight; Brain; Cannabinoid Receptor Modulators; Cannabinoids; Dose-Response Relationship, Drug; Drug Synergism; Homeostasis; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Obesity; Opioid Peptides; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1 | 2004 |
Chronic administration of nalmefene leads to increased food intake and body weight gain in mice.
Topics: Administration, Oral; Animals; Diet; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Eating; Energy Intake; Intubation, Gastrointestinal; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Receptors, Opioid; Time Factors; Weight Gain | 2004 |
Implantable technology for long-term delivery of nalmefene for treatment of alcoholism.
Topics: Alcoholism; Animals; Area Under Curve; Delayed-Action Preparations; Equipment Design; Humans; Infusion Pumps, Implantable; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Technology, Pharmaceutical | 2004 |
Determination of nalmefene by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.
Topics: Animals; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Injections, Intravenous; Naltrexone; Rabbits; Reference Standards; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Time Factors | 2005 |
Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
Topics: Adolescent; Adult; Analgesics, Opioid; Animals; Benzeneacetamides; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Estradiol; Female; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Male; Naltrexone; Narcotic Antagonists; Prolactin; Pyrrolidines; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2005 |
Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene.
Topics: Adrenocorticotropic Hormone; Adult; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Pituitary-Adrenal System; Stimulation, Chemical | 2005 |
Pharmacotherapy for erectile dysfunction.
Topics: alpha-MSH; Apomorphine; Dopamine Agonists; Drug Therapy, Combination; Erectile Dysfunction; Humans; Isoquinolines; Male; Naltrexone; Naphthyridines; Neuroprotective Agents; Peptides, Cyclic; Phosphodiesterase Inhibitors; Selective Serotonin Reuptake Inhibitors; Sexual Behavior; Trazodone | 2004 |
Pathological gambling: focusing on the addiction, not the activity.
Topics: Behavior, Addictive; Gambling; Humans; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Receptors, Opioid; Substance-Related Disorders; Treatment Outcome | 2006 |
Optimization of the preparation of nalmefene-loaded sustained-release microspheres using central composite design.
Topics: Delayed-Action Preparations; Drug Design; Forecasting; Glycolates; Lactic Acid; Microspheres; Models, Theoretical; Naltrexone; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2006 |
Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.
Topics: Amino Acid Sequence; Animals; Benzeneacetamides; Biomarkers; Cloning, Molecular; Diterpenes; Diterpenes, Clerodane; Female; Hallucinogens; Humans; Macaca mulatta; Male; Molecular Sequence Data; Naltrexone; Prolactin; Pyrrolidines; Receptors, Opioid, kappa; Sex Characteristics | 2007 |
The permeation of nalmefene hydrochloride across different regions of ovine nasal mucosa.
Topics: Animals; Biological Transport; Cell Membrane Permeability; Male; Naltrexone; Nasal Mucosa; Sheep; Turbinates | 2006 |
Application of a sensitive liquid chromatographic/tandem mass spectrometric method to pharmacokinetic study of nalmefene in humans.
Topics: Adult; Chromatography, Liquid; Humans; Male; Naltrexone; Narcotic Antagonists; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2007 |
Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food.
Topics: Adiposity; Animals; Anxiety; Behavior, Animal; Body Weight; Eating; Feeding Behavior; Female; Food; Food Preferences; Ghrelin; Growth Hormone; Leptin; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Rats; Rats, Wistar | 2008 |
Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.
Topics: Administration, Inhalation; Alcoholism; Animals; Central Nervous System Depressants; Conditioning, Operant; Data Interpretation, Statistical; Dynorphins; Ethanol; Injections, Intraventricular; Male; Motivation; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Self Administration; Substance Withdrawal Syndrome | 2008 |
Preclinical models to evaluate potential pharmacotherapeutic agents in treating alcoholism and studying the neuropharmacological bases of ethanol-seeking behaviors in rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Behavior, Addictive; Disease Models, Animal; Drug Evaluation, Preclinical; Ethanol; Female; Male; Naltrexone; Rats; Reinforcement Schedule | 2002 |
Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers.
Topics: Adult; Alcohol-Related Disorders; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Receptors, Opioid; Treatment Outcome | 2008 |
In vivo characterization of the opioid antagonist nalmefene in mice.
Topics: Analgesics, Opioid; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Inhibitory Concentration 50; Male; Mice; Mice, Inbred ICR; Morphine; Motor Activity; Naltrexone; Narcotic Antagonists; Pain; Substance Withdrawal Syndrome; Time Factors | 2010 |
Opioid-like compound exerts anti-fibrotic activity via decreased hepatic stellate cell activation and inflammation.
Topics: Actins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Proliferation; Cell Survival; Cells, Cultured; Chemical and Drug Induced Liver Injury; Collagen; Disease Models, Animal; Hepatic Stellate Cells; Immunoblotting; Liver Cirrhosis; Male; Matrix Metalloproteinase 13; Matrix Metalloproteinase 2; Morphinans; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Electromembrane extraction of trace amounts of naltrexone and nalmefene from untreated biological fluids.
Topics: Chemical Fractionation; Ethers; Humans; Linear Models; Membranes, Artificial; Naltrexone; Organophosphates; Reproducibility of Results | 2011 |
Structural basis for μ-opioid receptor binding and activation.
Topics: Amino Acid Substitution; Animals; Binding Sites; Binding, Competitive; Cattle; Cyclic AMP; Databases, Factual; Decapodiformes; Diprenorphine; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Molecular Dynamics Simulation; Morphine; Mutagenesis, Site-Directed; Naltrexone; Protein Binding; Radioligand Assay; Receptors, Opioid, mu; Small Molecule Libraries | 2011 |
Low-voltage electrically-enhanced microextraction as a novel technique for simultaneous extraction of acidic and basic drugs from biological fluids.
Topics: Chromatography, High Pressure Liquid; Diclofenac; Electrochemical Techniques; Humans; Hydrochloric Acid; Hydrogen-Ion Concentration; Limit of Detection; Liquid Phase Microextraction; Membranes, Artificial; Naltrexone; Pharmaceutical Preparations; Reproducibility of Results; Sodium Hydroxide; Solvents | 2012 |
Pulsed electromembrane extraction: a new concept of electrically enhanced extraction.
Topics: Chemical Fractionation; Chromatography, High Pressure Liquid; Electrochemical Techniques; Humans; Hydrogen-Ion Concentration; Limit of Detection; Membranes, Artificial; Naltrexone; Regression Analysis; Reproducibility of Results | 2012 |
Opioid receptors control viral replication in the airways.
Topics: Analgesics, Opioid; Animals; Bronchiolitis; Case-Control Studies; Chemokines; Female; Genome-Wide Association Study; Humans; Infant; Interleukin-6; Mice; Mice, Inbred BALB C; Naltrexone; Narcotic Antagonists; Polymorphism, Genetic; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, mu; Respiration, Artificial; Respiratory Syncytial Virus Infections; Respiratory System; Signal Transduction; Viral Load; Virus Replication | 2013 |
Naltrexone and nalmefene: any meaningful difference?
Topics: Alcoholism; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Secondary Prevention | 2013 |
Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2014 |
Bad medicine: using surrogate markers.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2014 |
▼Nalmefene for alcohol dependence.
Topics: Alcohol Drinking; Alcoholism; Drug Approval; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Prevalence; Sex Factors; United Kingdom | 2014 |
Nalmefene reverses carfentanil-induced loss of righting reflex and respiratory depression in rats.
Topics: Analgesics, Opioid; Animals; Blood Gas Analysis; Dose-Response Relationship, Drug; Fentanyl; Male; Naltrexone; Rats; Rats, Sprague-Dawley; Reflex, Righting; Respiratory Insufficiency; Time Factors | 2014 |
The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours.
Topics: Analgesics, Opioid; Animals; CHO Cells; Compulsive Behavior; Cricetinae; Cricetulus; Guanosine 5'-O-(3-Thiotriphosphate); HEK293 Cells; Humans; Indans; Ligands; Male; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Protein Binding; Receptors, Opioid, mu; Reward; Treatment Outcome; Triazoles | 2015 |
Nalmefene. Alcohol dependence: no advance.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Patient Safety; Patient Selection; Risk Assessment; Risk Factors; Treatment Outcome | 2014 |
A predictive microsimulation model to estimate the clinical relevance of reducing alcohol consumption in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Computer Simulation; England; Female; Harm Reduction; Humans; Logistic Models; Male; Middle Aged; Models, Theoretical; Naltrexone; Narcotic Antagonists; Wounds and Injuries | 2014 |
Decision to recommend drug to cut drink dependence proves controversial.
Topics: Administration, Oral; Adult; Alcoholism; Decision Making; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Patient Selection; Practice Guidelines as Topic; Risk Assessment; State Medicine; Treatment Outcome; United Kingdom | 2014 |
Neuroprotection of nalmefene for postoperative patients with spontaneous intracerebral hemorrhage.
Topics: Adult; Aged; Cerebral Hemorrhage; China; Female; Humans; Male; Middle Aged; Naltrexone; Neuroimaging; Neuroprotective Agents; Postoperative Complications; Retrospective Studies; Severity of Illness Index; Stroke; Treatment Outcome | 2015 |
A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice.
Topics: Alcohol Drinking; Animals; Conditioning, Operant; Electric Stimulation; Ethanol; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Naltrexone; Receptors, Opioid, mu; Reward; Self Administration | 2015 |
German evaluation says new drug for alcohol dependence is no better than old one.
Topics: Alcohol Deterrents; Alcoholism; Germany; Humans; Naltrexone | 2014 |
Treatment of cocaine craving with as-needed nalmefene, a partial κ opioid receptor agonist: first clinical experience.
Topics: Adult; Behavior, Addictive; Cocaine-Related Disorders; Craving; Drug Partial Agonism; Female; Humans; Naltrexone; Narcotic Antagonists; Receptors, Opioid, kappa; Recurrence; Time Factors; Treatment Outcome | 2015 |
In Vitro and In Vivo Evaluations of PLGA Microspheres Containing Nalmefene.
Topics: Animals; Drug Carriers; Drug Liberation; Female; Guinea Pigs; Lactic Acid; Male; Materials Testing; Mice; Microspheres; Naltrexone; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats | 2015 |
[Influence of nalmefene on psychosocial intervention in alcohol-dependent patients].
Topics: Alcohol Deterrents; Alcoholism; Humans; Naltrexone | 2015 |
Severe opioid withdrawal syndrome after a single dose of nalmefene.
Topics: Adult; Alcoholism; Analgesics, Opioid; Codeine; Contraindications; Drug Interactions; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2015 |
The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients.
Topics: Adult; Alcohol Drinking; Alcoholism; Demography; Female; Humans; Male; Middle Aged; Naltrexone; Patient Outcome Assessment; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2015 |
[Reduction of consumption as the first goal of therapy].
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2015 |
The T-peak-T-end interval as a marker of repolarization abnormality: a comparison with the QT interval for five different drugs.
Topics: Adult; Biomarkers; Clinical Trials as Topic; Dihydropyridines; Electrocardiography; Female; Fluoroquinolones; Humans; Imidazoles; Indoles; Male; Moxifloxacin; Naltrexone; Pharmaceutical Preparations; Sotalol | 2015 |
[Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Alcoholism; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Pharmacovigilance; Substance Withdrawal Syndrome | 2015 |
Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.
Topics: Administration, Oral; Alcoholism; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Injections, Intravenous; Models, Biological; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu | 2016 |
[Alcohol use disorders: current approaches to diagnosis and treatment].
Topics: Alcohol Drinking; Alcoholism; Diagnostic and Statistical Manual of Mental Disorders; Ethanol; Female; Humans; International Classification of Diseases; Male; Naltrexone; Narcotic Antagonists; Remission Induction | 2015 |
Effectiveness of Nalmefene in Binge Eating Disorder: A Case Report.
Topics: Adult; Appetite Depressants; Binge-Eating Disorder; Female; Humans; Naltrexone; Treatment Outcome | 2016 |
Effects of lisdexamfetamine in a rat model of binge-eating.
Topics: Animals; Baclofen; Behavior, Animal; Benzazepines; Benzodiazepines; Body Weight; Bulimia; Disease Models, Animal; Eating; Feeding Behavior; Female; Idazoxan; Lisdexamfetamine Dimesylate; Naltrexone; Olanzapine; Prazosin; Prodrugs; Raclopride; Rats; Rats, Wistar; Rolipram | 2015 |
Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
Topics: Adult; Alcohol Drinking; Analgesics, Opioid; Buprenorphine; Drug Interactions; Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Substance Withdrawal Syndrome | 2016 |
Clinical experience about an unexpected adverse event during nalmefene treatment in two patients with alcohol use disorder.
Topics: Aged; Alcoholism; Disorders of Excessive Somnolence; Fatigue; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists | 2016 |
Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Alcohols; Craving; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sodium Oxybate; Treatment Outcome | 2016 |
The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.
Topics: Adolescent; Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Combined Modality Therapy; Cost of Illness; Cost-Benefit Analysis; Crime; Efficiency; Female; Health Care Costs; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Naltrexone; Patient Acceptance of Health Care; Psychotherapy; Risk; United Kingdom; Young Adult | 2016 |
Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors.
Topics: Alcoholism; Animals; Brain; Disease Models, Animal; Ethanol; Female; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid | 2017 |
Lipophilic nalmefene prodrugs to achieve a one-month sustained release.
Topics: Animals; Carbamates; Delayed-Action Preparations; Dogs; Fatty Acids; Female; Glutarates; Male; Naltrexone; Narcotic Antagonists; Prodrugs; Swine; Swine, Miniature | 2016 |
Nalmefene is effective at reducing alcohol seeking, treating alcohol-cocaine interactions and reducing alcohol-induced histone deacetylases gene expression in blood.
Topics: Alcohol Drinking; Animals; Cocaine; Dose-Response Relationship, Drug; Drug Interactions; Ethanol; Gene Expression Regulation, Enzymologic; Histone Deacetylases; Male; Naltrexone; Rats; Rats, Wistar; Structure-Activity Relationship | 2016 |
Cost-Effectiveness of Nalmefene: Exaggerated Expectations or Fallacy?
Topics: Alcoholism; Cost-Benefit Analysis; Humans; Naltrexone; Narcotic Antagonists; Treatment Outcome | 2016 |
A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence.
Topics: Alcohol Drinking; Alcoholism; Clinical Trials as Topic; Computer Simulation; Europe; Harm Reduction; Humans; Multicenter Studies as Topic; Naltrexone; Narcotic Antagonists; Outcome and Process Assessment, Health Care; Public Health; Social Support | 2016 |
Comparing Nalmefene and Naltrexone in Alcohol Dependence: Is there a Spin?
Topics: Alcoholism; Appetite Depressants; Double-Blind Method; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic | 2016 |
Marketing Status and Perceived Efficacy of Drugs for Supporting Abstinence and Reducing Alcohol Intake in Alcohol Use Disorders: A Survey among European Federation of Addiction Societies in Europe.
Topics: Acamprosate; Alcohol Abstinence; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Europe; Humans; Marketing; Naltrexone; Narcotic Antagonists; Perception; Practice Guidelines as Topic; Societies, Medical; Surveys and Questionnaires; Taurine; Treatment Outcome | 2016 |
A Comparison of Markov and Discrete-Time Microsimulation Approaches: Simulating the Avoidance of Alcohol-Attributable Harmful Events from Reduction of Alcohol Consumption Through Treatment of Alcohol Dependence.
Topics: Adult; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Female; Humans; Naltrexone | 2016 |
Distinct Effects of Nalmefene on Dopamine Uptake Rates and Kappa Opioid Receptor Activity in the Nucleus Accumbens Following Chronic Intermittent Ethanol Exposure.
Topics: Animals; Central Nervous System Depressants; Dopamine; Ethanol; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Receptors, Opioid, kappa | 2016 |
Evaluation in alcohol use disorders - insights from the nalmefene experience.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Female; Harm Reduction; Humans; Male; Naltrexone; Narcotic Antagonists | 2016 |
▼Nalmefene-time for last orders?
Topics: Alcoholism; Clinical Trials as Topic; Humans; Naltrexone; Narcotic Antagonists | 2016 |
Nalmefene for alcohol dependence: a NICE decision?
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists; Practice Guidelines as Topic; State Medicine; United Kingdom | 2016 |
Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine.
Topics: Adult; Aged; Alcoholism; Analgesics, Opioid; Female; France; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Pancreatitis; Retrospective Studies; Substance Withdrawal Syndrome | 2017 |
Nalmefene Prevents Alcohol-Induced Neuroinflammation and Alcohol Drinking Preference in Adolescent Female Mice: Role of TLR4.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Animals; Astrocytes; Cell Death; Chemokines; Drug Evaluation, Preclinical; Ethanol; Female; Membrane Microdomains; Mice, Inbred C57BL; Mice, Knockout; Myelin Sheath; Naloxone; Naltrexone; Narcotic Antagonists; Primary Cell Culture; Toll-Like Receptor 4 | 2017 |
More Treatments on Deck for Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic Acids; Cytidine Diphosphate Choline; Disulfiram; Drug Repositioning; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Mifepristone; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Off-Label Use; Patient Acceptance of Health Care; Taurine; Topiramate; United States; Varenicline | 2017 |
Nalmefene in Alcohol Use Disorder Subjects with Psychiatric Comorbidity: A Naturalistic Study.
Topics: Adult; Alcohol-Related Disorders; Alcoholism; Comorbidity; Female; Humans; Male; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists | 2017 |
Naltrexone- or Nalmefene-Related Buprenorphine Withdrawal: Treat It With… More Buprenorphine.
Topics: Alcoholism; Antisocial Personality Disorder; Buprenorphine; Heroin Dependence; Humans; Male; Medication Errors; Middle Aged; Naltrexone; Narcotic Antagonists; Substance Withdrawal Syndrome | 2017 |
Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cell Proliferation; Depression; Depressive Disorder; Disease Models, Animal; Hippocampus; Interferon-alpha; Male; Naltrexone; Narcotic Antagonists; Neurons; Rats, Wistar; Receptors, Opioid | 2018 |
Cost-Effectiveness of Nalmefene Added to Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol-Dependent Patients With High/Very High Drinking Risk Levels: A Microsimulation Model.
Topics: Alcohol Drinking; Alcoholism; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Naltrexone; Quality-Adjusted Life Years; Risk | 2017 |
Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts.
Topics: Animals; Body Weight; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Immunologic Factors; Lung; Mice, Inbred BALB C; Naltrexone; Narcotic Antagonists; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus Vaccines; T-Lymphocyte Subsets; Viral Load | 2018 |
Nalmefene attenuates malignant potential in colorectal cancer cell via inhibition of opioid receptor.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Movement; Cell Survival; Colorectal Neoplasms; Glycolysis; Mice; Naltrexone; Narcotic Antagonists; Oxygen Consumption; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Opioid; Signal Transduction | 2018 |
Commentary on Palpacuer et al. (2018): Do small effects on total alcohol consumption translate into clinical practice?
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Baclofen; Humans; Naltrexone; Narcotic Antagonists; Network Meta-Analysis; Topiramate | 2018 |
Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2018 |
Severe central sleep apnoea associated with nalmefene: a case report.
Topics: Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Polysomnography; Sleep Apnea, Central | 2018 |
Reply to Braillon et al.: Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?
Topics: Alcoholism; Humans; Naltrexone; Narcotic Antagonists | 2018 |
Evaluation of alcohol use disorders pharmacotherapies in a new preclinical model of binge drinking.
Topics: Acamprosate; Animals; Baclofen; Binge Drinking; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Extinction, Psychological; Hydroxybutyrates; Male; Motivation; Naltrexone; Rats; Self Administration | 2018 |
Naltrexone and nalmefene attenuate cocaine place preference in male mice.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesia; Analgesics, Opioid; Animals; Cocaine; Conditioning, Psychological; Dose-Response Relationship, Drug; Locomotion; Male; Mice; Morphine; Naltrexone; Narcotic Antagonists | 2018 |
[Illogical association nalmefene and opioids: Analysis in the French pharmacovigilance database].
Topics: Analgesics, Opioid; Databases, Factual; Drug Labeling; France; Humans; Methadone; Naltrexone; Narcotic Antagonists; Pharmacovigilance | 2019 |
Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.
Topics: Acamprosate; Administrative Claims, Healthcare; Adult; Aged; Alcohol Deterrents; Alcoholism; Baclofen; Databases, Factual; Dose-Response Relationship, Drug; Female; Follow-Up Studies; France; Hospitalization; Humans; Male; Middle Aged; Naltrexone; Off-Label Use; Risk Assessment; Socioeconomic Factors | 2018 |
Short term exposure to oxycodone alters the survival, proliferation and differentiation of rat embryonic neural stem cell in vitro.
Topics: Analgesics, Opioid; Animals; Apoptosis; Cell Differentiation; Cell Proliferation; Cell Survival; Embryonic Stem Cells; Female; Morphine; Naltrexone; Neural Stem Cells; Oxycodone; Pregnancy; Rats; Rats, Sprague-Dawley | 2018 |
Use of drugs for alcohol use disorder in Norway 2004–16.
Topics: Acamprosate; Adult; Alcohol Deterrents; Alcohol-Related Disorders; Disulfiram; Drug Prescriptions; Drug Utilization; Female; Humans; Male; Middle Aged; Naltrexone; Norway; Registries | 2018 |
Simultaneous extraction of acidic and basic drugs via on-chip electromembrane extraction using a single-compartment microfluidic device.
Topics: Chromatography, High Pressure Liquid; Diclofenac; Electrochemical Techniques; Lab-On-A-Chip Devices; Membranes, Artificial; Naltrexone; Polymethyl Methacrylate; Time Factors | 2019 |
Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis.
Topics: Alcohol Drinking; Alcoholism; Humans; Meta-Analysis as Topic; Naltrexone; Narcotic Antagonists; Research Design | 2019 |
Nalmefene in alcohol-dependent patients with a high drinking risk: A limited efficacy in reducing alcohol consumption.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2020 |
Response to 'Nalmefene in alcohol-dependent patients with a high drinking risk: A limited efficacy in reducing alcohol consumption'.
Topics: Alcohol Drinking; Alcoholism; Humans; Naltrexone | 2020 |
Effects of nalmefene hydrochloride on TLR4 signaling pathway in rats with lung ischemia-reperfusion injury.
Topics: Acute Lung Injury; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Naltrexone; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Signal Transduction; Thoracotomy; Toll-Like Receptor 4 | 2020 |
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression.
Topics: Animals; Behavior Observation Techniques; Behavior, Animal; Depression; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Repositioning; Female; Humans; Male; Mice; Mice, Knockout; Naltrexone; Nucleus Accumbens; Receptors, Opioid, kappa; Receptors, Opioid, mu; Sex Factors | 2020 |
Nalmefene as Needed Use Needs Evidence for Harm/Benefit Ratio.
Topics: Humans; Naltrexone; Narcotic Antagonists | 2020 |
Response to Dr Braillon.
Topics: Naltrexone | 2020 |
GluN2A-selective positive allosteric modulator-nalmefene-flumazenil reverses ketamine-fentanyl-dexmedetomidine-induced anesthesia and analgesia in rats.
Topics: Adjuvants, Anesthesia; Allosteric Regulation; Analgesia; Anesthesia; Animals; Delayed Emergence from Anesthesia; Dexmedetomidine; Drug Combinations; Drug Evaluation, Preclinical; Female; Fentanyl; Flumazenil; GABA-A Receptor Antagonists; Ketamine; Male; Maze Learning; Naltrexone; Narcotic Antagonists; Nociception; Pain Measurement; Rats; Receptors, N-Methyl-D-Aspartate; Reflex, Righting; Rotarod Performance Test | 2020 |
[Alcohol dependence and opioid receptor -Pharmacological profile of nalmefene].
Topics: Alcoholism; Animals; Clinical Trials as Topic; Humans; Japan; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid | 2020 |
[Four cases of alcoholic liver cirrhosis in alcohol-dependent patients treated with nalmefene].
Topics: Alcohol Drinking; Alcoholism; Europe; Humans; Japan; Liver Cirrhosis, Alcoholic; Naltrexone | 2021 |
Occupational allergic contact dermatitis caused by nalmefene.
Topics: Adult; Chemical Industry; Dermatitis, Allergic Contact; Dermatitis, Occupational; Facial Dermatoses; Humans; Male; Middle Aged; Naltrexone; Patch Tests | 2021 |
Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcoholism; Female; Humans; Insurance Claim Review; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Prospective Studies; Treatment Outcome; Young Adult | 2021 |
Nalmefene, a mu opioid receptor antagonist/kappa opioid receptor partial agonist, potentiates cocaine motivation but not intake with extended access self-administration in adult male mice.
Topics: Analgesics, Opioid; Animals; Cocaine; Male; Mice; Mice, Inbred C57BL; Motivation; Naltrexone; Narcotic Antagonists; Receptors, Opioid, kappa; Receptors, Opioid, mu; Self Administration | 2021 |
Nalmefene non-enantioselectively targets myeloid differentiation protein 2 and inhibits toll-like receptor 4 signaling: wet-lab techniques and
Topics: Animals; Cells, Cultured; Humans; Hydrophobic and Hydrophilic Interactions; Lymphocyte Antigen 96; Mice; Molecular Conformation; Molecular Dynamics Simulation; Naltrexone; Narcotic Antagonists; Signal Transduction; Stereoisomerism; Thermodynamics; Toll-Like Receptor 4 | 2021 |
Safety and Persistence of Nalmefene Treatment for Alcohol Dependence. Results from Two Post-authorisation Safety Studies.
Topics: Adult; Alcoholism; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Outcome Assessment, Health Care; Prospective Studies; Retrospective Studies | 2021 |
[Treatment of dissociative symptoms with nalmefene in patients with borderline personality disorder and complex posttraumatic stress disorder].
Topics: Borderline Personality Disorder; Dissociative Disorders; Humans; Naltrexone; Stress Disorders, Post-Traumatic | 2022 |
Effect of Different Absorption Enhancers on the Nasal Absorption of Nalmefene Hydrochloride.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Intranasal; Animals; Naltrexone; Nasal Absorption; Nasal Mucosa; Rats | 2022 |
Nalmefene returns for reversal of opioid overdose.
Topics: Humans; Naltrexone; Narcotic Antagonists; Opiate Overdose | 2022 |
Effect of Sufentanil Combined with Nalmefene Assisted Surface Anesthesia on Transnasal Endotracheal Intubation Guided by Fiberoptic Bronchoscope.
Topics: Anesthesia; Bronchoscopes; Fiber Optic Technology; Humans; Intubation, Intratracheal; Naltrexone; Retrospective Studies; Sufentanil | 2022 |
FDA Approves Nalmefene, a Longer-Lasting Opioid Reversal Nasal Spray.
Topics: Analgesics, Opioid; Drug Approval; Naltrexone; Narcotic Antagonists; Nasal Sprays; Time Factors; United States | 2023 |
Nalmefene attenuates reinstatement of methamphetamine-seeking behavior in rats through group II metabotropic glutamate receptors (mGluR2/3).
Topics: Animals; Cues; Drug-Seeking Behavior; Extinction, Psychological; Methamphetamine; Naltrexone; Rats; Receptors, Metabotropic Glutamate; Self Administration | 2024 |
Nalmefene nasal spray (Opvee) for reversal of opioid overdose.
Topics: Analgesics, Opioid; Drug Overdose; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Nasal Sprays; Opiate Overdose | 2023 |